Amedeo Smart

Free Medical Literature Service

 

Amedeo

Prostate Cancer
  Free Subscription

Articles published in
Eur Urol
    November 2024
  1. MADEC FX, Mesnard B, Dariane C
    Re: Prevalence and Factors Associated with Prostate Cancer Among Transgender Women.
    Eur Urol. 2024 Nov 21:S0302-2838(24)02704-0. doi: 10.1016/j.eururo.2024.
    >> Share

  2. COOPERBERG MR
    Re: Artificial Intelligence and Radiologists in Prostate Cancer Detection on MRI (PI-CAI): An International, Paired, Non-inferiority, Confirmatory Study.
    Eur Urol. 2024 Nov 21:S0302-2838(24)02700-3. doi: 10.1016/j.eururo.2024.
    >> Share

  3. HUGOSSON J
    Population-based Screening for Prostate Cancer: Is it Time?
    Eur Urol. 2024 Nov 20:S0302-2838(24)02696-4. doi: 10.1016/j.eururo.2024.
    >> Share

  4. DAHM P, Wilt TJ
    Re: Radical Prostatectomy or Watchful Waiting in Early Prostate Cancer.
    Eur Urol. 2024 Nov 15:S0302-2838(24)02687-3. doi: 10.1016/j.eururo.2024.
    >> Share

  5. KISHAN AU, Lamb JM, Wilhalme H, Casado M, et al
    Magnetic Resonance Imaging Versus Computed Tomography Guidance for Stereotactic Body Radiotherapy in Prostate Cancer: 2-year Outcomes from the MIRAGE Randomized Clinical Trial.
    Eur Urol. 2024 Nov 12:S0302-2838(24)02688-5. doi: 10.1016/j.eururo.2024.
    >> Share

  6. GHADJAR P, Zips D
    Re: Duration of Androgen Deprivation Therapy with Postoperative Radiotherapy for Prostate Cancer: A Comparison of Long-course Versus Short-course Androgen Deprivation Therapy in the RADICALS-HD Randomised Trial.
    Eur Urol. 2024 Nov 12:S0302-2838(24)02691-5. doi: 10.1016/j.eururo.2024.
    >> Share

  7. ARMSTRONG WR, Kishan AU, Booker KM, Grogan TR, et al
    Corrigendum to "Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774)" [
    Eur Urol. 2024 Nov 8:S0302-2838(24)02684-8. doi: 10.1016/j.eururo.2024.
    >> Share

  8. PARKER CC, Clarke NW, Cook AD, Petersen PM, et al
    Randomised Trial of No, Short-term, or Long-term Androgen Deprivation Therapy with Postoperative Radiotherapy After Radical Prostatectomy: Results from the Three-way Comparison of RADICALS-HD (NCT00541047).
    Eur Urol. 2024;86:422-430.
    >> Share

  9. LANE BR, Dess RT, Borza T
    More Than Words: Defining Adjuvant, Consolidative, and Salvage Treatment after Radical Prostatectomy.
    Eur Urol. 2024;86:385-387.
    >> Share

    October 2024
  10. OH WK, Agarwal N, Bryce A, Barata P, et al
    What's in a Name? Why Words Matter in Advanced Prostate Cancer.
    Eur Urol. 2024 Oct 28:S0302-2838(24)02680-0. doi: 10.1016/j.eururo.2024.
    >> Share

  11. TOUIJER KA, Vertosick EA, Sjoberg DD, Liso N, et al
    Pelvic Lymph Node Dissection in Prostate Cancer: Update from a Randomized Clinical Trial of Limited Versus Extended Dissection.
    Eur Urol. 2024 Oct 28:S0302-2838(24)02647-2. doi: 10.1016/j.eururo.2024.
    >> Share

  12. TWILT JJ, Saha A, Bosma JS, van Ginneken B, et al
    Evaluating Biparametric Versus Multiparametric Magnetic Resonance Imaging for Diagnosing Clinically Significant Prostate Cancer: An International, Paired, Noninferiority, Confirmatory Observer Study.
    Eur Urol. 2024 Oct 21:S0302-2838(24)02640-X. doi: 10.1016/j.eururo.2024.
    >> Share

  13. VANDERWEELE DJ, Hussain M
    Management Decisions for Metastatic Castration-resistant Prostate Cancer in 2024.
    Eur Urol. 2024 Oct 19:S0302-2838(24)02646-0. doi: 10.1016/j.eururo.2024.
    >> Share

  14. EVANGELISTA L, Cecchi L, Zucali PA
    Advancing Prostate Cancer Care: Prostate-specific Membrane Antigen-based Radioligand Therapy at the Forefront.
    Eur Urol. 2024 Oct 19:S0302-2838(24)02645-9. doi: 10.1016/j.eururo.2024.
    >> Share

  15. FENDLER WP, Grunwald V, Herrmann K, Hadaschik BA, et al
    Prostate-specific Membrane Antigen (PSMA) Spatial Biomarker: Standardized Positron Emission Tomography Disease Maps Provide Accurate Prediction of Overall Survival in Prostate Cancer.
    Eur Urol. 2024 Oct 19:S0302-2838(24)02648-4. doi: 10.1016/j.eururo.2024.
    >> Share

  16. GILLESSEN S, Turco F, Davis ID, Efstathiou JA, et al
    Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC).
    Eur Urol. 2024 Oct 10:S0302-2838(24)02610-1. doi: 10.1016/j.eururo.2024.
    >> Share

  17. BAKHT MK, Beltran H
    Aiming High: Prostate-specific Membrane Antigen Expression in Treatment-naive Prostate Cancer.
    Eur Urol. 2024 Oct 10:S0302-2838(24)02637-X. doi: 10.1016/j.eururo.2024.
    >> Share

  18. ONG WL, Loblaw A
    Radiotherapy for Unfavorable-risk Prostate Cancer: Biologic Dose Escalation, Fewer Fractions, or Both?
    Eur Urol. 2024 Oct 9:S0302-2838(24)02636-8. doi: 10.1016/j.eururo.2024.
    >> Share

  19. ROUVIERE O, van Leenders GJLH, Eberli D
    Systematic Prostate Biopsy Versus Perilesional Sampling: If It Isn't Broke, Why Fix It?
    Eur Urol. 2024;86:295-296.
    >> Share

  20. BROWN JR, Sonpavde GP, Calaway A, Barata PC, et al
    Circulating Tumor DNA To Assess Minimal Residual Disease: Versatile, but How Valuable?
    Eur Urol. 2024;86:312-314.
    >> Share

  21. CIMADAMORE A, Giannarini G, Crestani A, Lopez-Beltran A, et al
    How To Report the Minor Component of a High-grade Pattern in Radical Prostatectomy Specimens: Time To Abandon the "Tertiary" Terminology?
    Eur Urol. 2024;86:291-294.
    >> Share

    September 2024
  22. GANDAGLIA G, Barletta F, Briganti A, Montorsi F, et al
    Re: Long-term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients with Low-Risk Prostate Cancer.
    Eur Urol. 2024 Sep 26:S0302-2838(24)02613-7. doi: 10.1016/j.eururo.2024.
    >> Share

  23. CARLSSON SV, Lilja H, Vickers AJ, Bjartell AS, et al
    Re: Early Prostate Cancer Deaths Among Men with Higher vs Lower Genetic Risk.
    Eur Urol. 2024 Sep 25:S0302-2838(24)02615-0. doi: 10.1016/j.eururo.2024.
    >> Share

  24. QI F
    Re: Niklas Klumper, Viktor Grunwald, Arndt Hartmann, et al. The Role of Microsatellite Instability/DNA Mismatch Repair Deficiency and Tumor Mutational Burden as Biomarkers in Predicting Response to Immunotherapy in Castration-resistant Prostate Cancer
    Eur Urol. 2024 Sep 25:S0302-2838(24)02612-5. doi: 10.1016/j.eururo.2024.
    >> Share

  25. VAN DEN BERGH RCN, Schoots IG, Cornford PA
    Standard Repeat Biopsies During Active Surveillance for Prostate Cancer: Are They Necessary in the Magnetic Resonance Imaging Era?
    Eur Urol. 2024 Sep 25:S0302-2838(24)02607-1. doi: 10.1016/j.eururo.2024.
    >> Share

  26. DAI YH, Chen PH, Lee DJ, Andrade G, et al
    A Meta-Analysis and Meta-Regression of the Efficacy, Toxicity, and Quality of Life Outcomes Following Prostate-Specific Membrane Antigen Radioligand Therapy Utilising Lutetium-177 and Actinium-225 in Metastatic Prostate Cancer.
    Eur Urol. 2024 Sep 25:S0302-2838(24)02608-3. doi: 10.1016/j.eururo.2024.
    >> Share

  27. RATHKOPF DE, Roubaud G, Chi KN, Efstathiou E, et al
    Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE Trial.
    Eur Urol. 2024 Sep 23:S0302-2838(24)02594-6. doi: 10.1016/j.eururo.2024.
    >> Share

  28. UNTERRAINER M, Unterrainer LM, Ilhan H
    Re: Robert Seifert, Louise Emmett, Steven P. Rowe, et al. Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2). Eur Urol 2023;83:405-12.
    Eur Urol. 2024 Sep 23:S0302-2838(24)02617-4. doi: 10.1016/j.eururo.2024.
    >> Share

  29. KLUMPER N, Eckstein M
    Reply to Feng Qi's Letter to the Editor re: Niklas Klumper, Viktor Grunwald, Arndt Hartmann, et al. The Role of Microsatellite Instability/DNA Mismatch Repair Deficiency and Tumor Mutational Burden as Biomarkers in Predicting Response to Immunotherapy
    Eur Urol. 2024 Sep 23:S0302-2838(24)02616-2. doi: 10.1016/j.eururo.2024.
    >> Share

  30. CHEN DC, Thomson A, Mazzone E, Perera ML, et al
    Re: Updated Analysis of Comparative Toxicity of Proton and Photon Radiation for Prostate Cancer.
    Eur Urol. 2024 Sep 20:S0302-2838(24)02513-2. doi: 10.1016/j.eururo.2024.
    >> Share

  31. FRANCINI E, Agarwal N, Castro E, Cheng HH, et al
    Intensification Approaches and Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer: A Systematic Review.
    Eur Urol. 2024 Sep 20:S0302-2838(24)02599-5. doi: 10.1016/j.eururo.2024.
    >> Share

  32. BOEVE LMS, Hulshof MCCM, Verhagen PCMS, Twisk JWR, et al
    Prostate Cancer-related Events in Patients with Synchronous Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Deprivation Therapy with and Without Concurrent Radiation Therapy to the Prostate; Data from the HORRAD Trial.
    Eur Urol. 2024 Sep 19:S0302-2838(24)02593-4. doi: 10.1016/j.eururo.2024.
    >> Share

  33. AZIZ MK, Molony D, Monlezun D, Holder T, et al
    Prostate Cancer Therapy Cardiotoxicity Map (PROXMAP) for Advanced Disease States: A Systematic Review and Network Meta-analysis with Bayesian Modeling of Treatment Histories.
    Eur Urol. 2024 Sep 18:S0302-2838(24)02569-7. doi: 10.1016/j.eururo.2024.
    >> Share

  34. WEINER AB, Agrawal R, Wang NK, Sonni I, et al
    Molecular Hallmarks of Prostate-specific Membrane Antigen in Treatment-naive Prostate Cancer.
    Eur Urol. 2024 Sep 17:S0302-2838(24)02597-1. doi: 10.1016/j.eururo.2024.
    >> Share

  35. BJERNER J, Bratt O, Aas K, Albertsen PC, et al
    Reply to Rongkang Li, Lei Peng, Shaohua Zhang, and Song Wu's Letter to the Editor re: Johan Bjerner, Ola Bratt, Kirsti Aas, et al. Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death-Results from the No
    Eur Urol. 2024 Sep 17:S0302-2838(24)02575-2. doi: 10.1016/j.eururo.2024.
    >> Share

  36. BRATT O
    Prostate Cancer Screening: Setting the Controls on the Mixing Board.
    Eur Urol. 2024 Sep 17:S0302-2838(24)02598-3. doi: 10.1016/j.eururo.2024.
    >> Share

  37. NIAZI T, Nabid A, Malagon T, Tisseverasinghe S, et al
    Hypofractionated Dose Escalation Radiotherapy for High-risk Prostate Cancer: The Survival Analysis of the Prostate Cancer Study 5, a Groupe de Radio-oncologie Genito-urinaire du Quebec-led Phase 3 Trial.
    Eur Urol. 2024 Sep 12:S0302-2838(24)02574-0. doi: 10.1016/j.eururo.2024.
    >> Share

  38. VAN AS N, Yasar B, Griffin C, Patel J, et al
    Radical Prostatectomy Versus Stereotactic Radiotherapy for Clinically Localised Prostate Cancer: Results of the PACE-A Randomised Trial.
    Eur Urol. 2024 Sep 11:S0302-2838(24)02568-5. doi: 10.1016/j.eururo.2024.
    >> Share

  39. LI R, Peng L, Zhang S, Wu S, et al
    Re: Johan Bjerner, Ola Bratt, Kirsti Aas, et al. Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death-Results from the Norwegian Prostate Cancer Consortium. Eur Urol 2024;86:20-6.
    Eur Urol. 2024 Sep 5:S0302-2838(24)02564-8. doi: 10.1016/j.eururo.2024.
    >> Share

  40. ARMSTRONG AJ, Sartor O, de Bono J, Chi K, et al
    Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [(177)Lu]Lu-PSMA-617 in the Phase 3 VISION Trial.
    Eur Urol. 2024 Sep 5:S0302-2838(24)02560-0. doi: 10.1016/j.eururo.2024.
    >> Share

  41. NAIR SS, Muhammad H, Jain P, Xie C, et al
    A Novel Artificial Intelligence-powered Tool for Precise Risk Stratification of Prostate Cancer Progression in Patients with Clinical Intermediate Risk.
    Eur Urol. 2024 Sep 3:S0302-2838(24)02496-5. doi: 10.1016/j.eururo.2024.
    >> Share

  42. KASIVISVANATHAN V, Wai-Shun Chan V, Clement KD, Levis B, et al
    VISION: An Individual Patient Data Meta-analysis of Randomised Trials Comparing Magnetic Resonance Imaging Targeted Biopsy with Standard Transrectal Ultrasound Guided Biopsy in the Detection of Prostate Cancer.
    Eur Urol. 2024 Sep 3:S0302-2838(24)02559-4. doi: 10.1016/j.eururo.2024.
    >> Share

  43. VYNCKIER P, Annemans L, Roobol M
    Reply to Andres Gutierrez, Julio Cesar Boada, and Sebastian Pena's Letter to the Editor re: Pieter Vynckier, Lieven Annemans, Sarah Raes, et al. Systematic Review on the Cost-effectiveness of Prostate Cancer Screening in Europe. Eur Urol. In press. ht
    Eur Urol. 2024 Sep 2:S0302-2838(24)02566-1. doi: 10.1016/j.eururo.2024.
    >> Share

  44. ACHARD V, Tombal B
    All Biochemical Recurrences Are Equal, but Some Are More Equal than Others.
    Eur Urol. 2024;86:211-212.
    >> Share

    August 2024
  45. GUTIERREZ A, Boada JC, Pena S
    Re: Pieter Vynckier, Lieven Annemans, Sarah Raes, et al. Systematic Review on the Cost Effectiveness of Prostate Cancer Screening in Europe. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.04.036.
    Eur Urol. 2024 Aug 30:S0302-2838(24)02565-X. doi: 10.1016/j.eururo.2024.
    >> Share

  46. LEENEN RCA, Venderbos LDF, Helleman J, Gomez Rivas J, et al
    Prostate Cancer Early Detection in the European Union and UK.
    Eur Urol. 2024 Aug 24:S0302-2838(24)02502-8. doi: 10.1016/j.eururo.2024.
    >> Share

  47. QI F
    Re: Wesley R. Armstrong, Amar U. Kishan, Kiara M. Booker, et al. Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter R
    Eur Urol. 2024 Aug 21:S0302-2838(24)02557-0. doi: 10.1016/j.eururo.2024.
    >> Share

  48. MAY M, Albersen M, Brookman-May S
    Re: Influential Factors Impacting Treatment Decision-making and Decision Regret in Patients with Localized or Locally Advanced Prostate Cancer: A Systematic Literature Review.
    Eur Urol. 2024 Aug 19:S0302-2838(24)02552-1. doi: 10.1016/j.eururo.2024.
    >> Share

  49. BRATT O
    Re: Prostate Cancers in the Prostate-specific Antigen Interval of 1.8-3 ng/ml: Results from the Goteborg-2 Prostate Cancer Screening Trial.
    Eur Urol. 2024 Aug 17:S0302-2838(24)02523-5. doi: 10.1016/j.eururo.2024.
    >> Share

  50. CHEN DC, Park H, McVey A, Lawrentschuk N, et al
    Re: Artificial Intelligence and Radiologists in Prostate Cancer Detection on MRI (PI-CAI): An International, Paired, Non-inferiority, Confirmatory Study.
    Eur Urol. 2024 Aug 17:S0302-2838(24)02520-X. doi: 10.1016/j.eururo.2024.
    >> Share

  51. GORADIA R, Abdollah F, Sood A
    Re: Integrative Multi-Region Molecular Profiling of Primary Prostate Cancer in Men with Synchronous Lymph Node Metastasis.
    Eur Urol. 2024 Aug 6:S0302-2838(24)02497-7. doi: 10.1016/j.eururo.2024.
    >> Share

  52. KAMRAN SC, Efstathiou JA
    Honing Stratification and Treatment for High-risk Prostate Cancer.
    Eur Urol. 2024 Aug 6:S0302-2838(24)02489-8. doi: 10.1016/j.eururo.2024.
    >> Share

  53. DI LORENZO G, Buonerba C
    Re: Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study.
    Eur Urol. 2024 Aug 1:S0302-2838(24)02500-4. doi: 10.1016/j.eururo.2024.
    >> Share

  54. THOMPSON IM JR
    Prostate-specific Antigen Screening in Limbo: How Low Should We Go?
    Eur Urol. 2024;86:101-102.
    >> Share

  55. MARRA G, Oderda M, Gontero P
    Re: Jim C. Hu, Melissa Assel, Mohamad E. Allaf, et al. Transrectal Magnetic Resonance Imaging-targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial. Eur Urol. 2024;86:61-68.
    Eur Urol. 2024;86:e36-e37.
    >> Share

    July 2024
  56. MONTORSI F, Longoni M, Briganti A, Gandaglia G, et al
    Re: Long-term Prostate Cancer-specific Mortality After Prostatectomy, Brachytherapy, External Beam Radiation Therapy, Hormonal Therapy, or Monitoring for Localized Prostate Cancer.
    Eur Urol. 2024 Jul 31:S0302-2838(24)02492-8. doi: 10.1016/j.eururo.2024.
    >> Share

  57. PARK H, Chen DC, Mazzone E, Grummet J, et al
    Re: Biomarker vs MRI-Enhanced Strategies for Prostate Cancer Screening. The STHLM3-MRI Randomized Clinical Trial.
    Eur Urol. 2024 Jul 19:S0302-2838(24)02452-7. doi: 10.1016/j.eururo.2024.
    >> Share

  58. MAZZONE E, Perera S, Neti AL, Chen DC, et al
    Re: [(177)Lu]Lu-PSMA-617 plus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer (ENZA-p): An Open-label, Multicentre, Randomised, Phase 2 Trial.
    Eur Urol. 2024 Jul 19:S0302-2838(24)02450-3. doi: 10.1016/j.eururo.2024.
    >> Share

  59. SPRATT DE, Liu VYT, Jia AY, Royce TJ, et al
    Meta-analysis of Individual Patient-level Data for a Multimodal Artificial Intelligence Biomarker in High-risk Prostate Cancer: Results from Six NRG/RTOG Phase 3 Randomized Trials.
    Eur Urol. 2024 Jul 17:S0302-2838(24)02454-0. doi: 10.1016/j.eururo.2024.
    >> Share

  60. HU JC, Schaeffer EM, Vickers AJ
    Reply to Ilias Giannakodimos' Letter to the Editor re: Jim C. Hu, Melissa Assel, Mohamad E. Allaf, et al. Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREV
    Eur Urol. 2024;86:e13.
    >> Share

  61. ROSEN GH, Chakiryan NH, Murray KS
    Re: Jim C. Hu, Melissa Assel, Mohamad E. Allaf, et al. Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial. Eur Urol. 2024;86:61-68.
    Eur Urol. 2024;86:e14.
    >> Share

  62. GIANNAKODIMOS I
    Re: Jim C. Hu, Melissa Assel, Mohamad E. Allaf, et al. Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial. Eur Urol. 2024;86:61-68.
    Eur Urol. 2024;86:e12.
    >> Share

  63. CHIU PK, Wu X, Gandaglia G
    Beyond Statistical Significance: Unveiling the Advantages of Transperineal Versus Transrectal Prostate Biopsies.
    Eur Urol. 2024;86:e16-e17.
    >> Share

  64. HU JC, Assel M, Allaf ME, Ehdaie B, et al
    Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial.
    Eur Urol. 2024;86:61-68.
    >> Share

    June 2024
  65. TANEJA SS
    Reducing or Increasing Overtreatment? How Do We Measure the Impact of Magnetic Resonance Imaging-targeted Biopsy on Prostate Cancer Mortality?
    Eur Urol. 2024 Jun 19:S0302-2838(24)02413-8. doi: 10.1016/j.eururo.2024.
    >> Share

  66. COOPERBERG MR
    PRECISE v2: An Enhanced Framework To Guide Future Research on the Use of Magnetic Resonance Imaging in Prostate Cancer Active Surveillance.
    Eur Urol. 2024 Jun 18:S0302-2838(24)02400-X. doi: 10.1016/j.eururo.2024.
    >> Share

  67. SRIVASTAVA A, Lewicki P, Morgan TM
    Biomarkers in Prostate Cancer Screening: Sometimes "More is More".
    Eur Urol. 2024 Jun 18:S0302-2838(24)02428-X. doi: 10.1016/j.eururo.2024.
    >> Share

  68. RAYCHAUDHURI R, DeJong M, Rettig M, Yu EY, et al
    Docetaxel and Carboplatin for the Treatment of Patients with Metastatic Castration-resistant Prostate Cancer and Biallelic Inactivation of Genes in the Homologous Recombination DNA Repair Pathway: The ABCD Trial.
    Eur Urol. 2024 Jun 17:S0302-2838(24)02407-2. doi: 10.1016/j.eururo.2024.
    >> Share

  69. MACEK P, Rodriguez-Sanchez L, Cathelineau X
    Re: Identification of the Optimal Candidates for Nodal Staging with Extended Pelvic Lymph Node Dissection Among Prostate Cancer Patients Who Underwent Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography. External Validation of
    Eur Urol. 2024 Jun 13:S0302-2838(24)02401-1. doi: 10.1016/j.eururo.2024.
    >> Share

  70. ADELEKE S
    High-performing, Accessible, and Affordable Imaging in Metastatic Prostate Cancer: Is Whole-body Magnetic Resonance Imaging the Answer?
    Eur Urol. 2024 Jun 12:S0302-2838(24)02410-2. doi: 10.1016/j.eururo.2024.
    >> Share

    May 2024
  71. VICKERS AJ
    Re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.0
    Eur Urol. 2024 May 25:S0302-2838(24)02385-6. doi: 10.1016/j.eururo.2024.
    >> Share

  72. ULERI A, Baboudjian M, Diamand R, Ploussard G, et al
    Reply to Hein V. Stroomberg, Klaus Brasso, and Andreas Roder's Letter to the Editor re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer L
    Eur Urol. 2024 May 24:S0302-2838(24)02387-X. doi: 10.1016/j.eururo.2024.
    >> Share

  73. ULERI A, Baboudjian M, Diamand R, Ploussard G, et al
    Reply to Andrew J. Vickers' Letter to the Editor re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment? Eur Urol. In
    Eur Urol. 2024 May 24:S0302-2838(24)02386-8. doi: 10.1016/j.eururo.2024.
    >> Share

  74. VYNCKIER P, Annemans L, Raes S, Amrouch C, et al
    Systematic Review on the Cost Effectiveness of Prostate Cancer Screening in Europe.
    Eur Urol. 2024 May 23:S0302-2838(24)02378-9. doi: 10.1016/j.eururo.2024.
    >> Share

  75. WEINER AB, Kakani P, Armstrong AJ, Bossi A, et al
    Risk Stratification of Patients with Recurrence After Primary Treatment for Prostate Cancer: A Systematic Review.
    Eur Urol. 2024 May 22:S0302-2838(24)02375-3. doi: 10.1016/j.eururo.2024.
    >> Share

  76. RAVI P, Xie W, Buyse M, Halabi S, et al
    Refining Risk Stratification of High-risk and Locoregional Prostate Cancer: A Pooled Analysis of Randomized Trials.
    Eur Urol. 2024 May 21:S0302-2838(24)02380-7. doi: 10.1016/j.eururo.2024.
    >> Share

  77. DALLA VOLTA A, Valcamonico F, Zivi A, Procopio G, et al
    Whole-body Diffusion-weighted Magnetic Resonance Imaging for Assessment of the Bone Response Rate in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Enzalutamide.
    Eur Urol. 2024 May 20:S0302-2838(24)02347-9. doi: 10.1016/j.eururo.2024.
    >> Share

  78. JOSEFSSON A, Mansson M, Kohestani K, Spyratou V, et al
    Performance of 4Kscore as a Reflex Test to Prostate-specific Antigen in the GOTEBORG-2 Prostate Cancer Screening Trial.
    Eur Urol. 2024 May 20:S0302-2838(24)02379-0. doi: 10.1016/j.eururo.2024.
    >> Share

  79. BROOKMAN-MAY SD, Buyse M, Freedland SJ, Miladinovic B, et al
    Challenges and Opportunities in Establishing Appropriate Intermediate Endpoints Reflecting Patient Benefit: A Roadmap for Research and Clinical Application in Nonmetastatic Prostate Cancer.
    Eur Urol. 2024 May 17:S0302-2838(24)02348-0. doi: 10.1016/j.eururo.2024.
    >> Share

  80. PADHANI AR, Lecouvet F, Petralia G, Koh DM, et al
    Re: Alonso Garcia-Ruiz, Carlos Macarro, Francesca Zacchi, et al. Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castration-resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical Trial. Eur Urol. In press. http
    Eur Urol. 2024 May 16:S0302-2838(24)02377-7. doi: 10.1016/j.eururo.2024.
    >> Share

  81. GARCIA-RUIZ A, Macarro C, Mateo J, Perez-Lopez R, et al
    Reply to Anwar R. Padhani, Frederic LeCouvet, Giuseppe Petralia, and Dow-Mu Koh's Letter to the Editor re: Alonso Garcia-Ruiz, Carlos Macarro, Francesca Zacchi, et al. Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castrati
    Eur Urol. 2024 May 16:S0302-2838(24)02376-5. doi: 10.1016/j.eururo.2024.
    >> Share

  82. FANKHAUSER CD, Wettstein MS, Wurnschimmel C, van Smeden M, et al
    Re: External Validation of the Rotterdam Prostate Cancer Risk Calculator and Comparison with Stockholm3 for Prostate Cancer Diagnosis in a Swedish Population-based Screening Cohort.
    Eur Urol. 2024 May 15:S0302-2838(24)02340-6. doi: 10.1016/j.eururo.2024.
    >> Share

  83. KRILAVICIUTE A, Kaaks R, Seibold P, de Vrieze M, et al
    Risk-adjusted Screening for Prostate Cancer-Defining the Low-risk Group by Data from the PROBASE Trial.
    Eur Urol. 2024 May 15:S0302-2838(24)02358-3. doi: 10.1016/j.eururo.2024.
    >> Share

  84. STROOMBERG HV, Brasso K, Roder A
    Re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.0
    Eur Urol. 2024 May 14:S0302-2838(24)02365-0. doi: 10.1016/j.eururo.2024.
    >> Share

  85. MERSEBURGER AS, Chowdhury S, Bahl A
    Therapy Optimization in the Management of Metastatic Hormone-sensitive Prostate Cancer: Insights from the ARASENS Study.
    Eur Urol. 2024 May 14:S0302-2838(24)02364-9. doi: 10.1016/j.eururo.2024.
    >> Share

  86. CHIN JL
    Re: Incidence and Survival of Secondary Malignancies after External Beam Radiotherapy for Prostate Cancer in the SEER Database.
    Eur Urol. 2024 May 13:S0302-2838(24)02344-3. doi: 10.1016/j.eururo.2024.
    >> Share

  87. KLUMPER N, Grunwald V, Hartmann A, Holzel M, et al
    The Role of Microsatellite Instability/DNA Mismatch Repair Deficiency and Tumor Mutational Burden as Biomarkers in Predicting Response to Immunotherapy in Castration-resistant Prostate Cancer.
    Eur Urol. 2024 May 13:S0302-2838(24)02350-9. doi: 10.1016/j.eururo.2024.
    >> Share

  88. OKOLI S, Okoli O, Ding H, Adeleke S, et al
    Re: Actinium-225-PSMA Radioligand Therapy of Metastatic Castration-resistant Prostate Cancer (WARMTH Act): A Multicentre, Retrospective Study.
    Eur Urol. 2024 May 11:S0302-2838(24)02352-2. doi: 10.1016/j.eururo.2024.
    >> Share

  89. LIGHT A, Mayor N, Cullen E, Kirkham A, et al
    The Transatlantic Recommendations for Prostate Gland Evaluation with Magnetic Resonance Imaging After Focal Therapy (TARGET): A Systematic Review and International Consensus Recommendations.
    Eur Urol. 2024;85:466-482.
    >> Share

  90. ANAND M, Jain B, Aggarwal S
    Re: Rudolf A. Werner, Philipp E. Hartrampf, Wolfgang P. Fendler, et al. Prostate-specific Membrane Antigen Reporting and Data System Version 2.0. Eur Urol 2023;84:491-502.
    Eur Urol. 2024;85:e145.
    >> Share

  91. HARTRAMPF PE, Rowe SP, Pomper MG, Higuchi T, et al
    Reply to Madhur Anand, Bela Jain, and Swati Aggarwal's Letter to the Editor re: Rudolf A. Werner, Philipp E. Hartrampf, Wolfgang P. Fendler, et al. Prostate-Specific Membrane Antigen Reporting and Data System Version 2.0. Eur Urol 2023;84:491-502.
    Eur Urol. 2024;85:e146-e147.
    >> Share

    April 2024
  92. TILKI D, van den Bergh RCN, Briers E, Van den Broeck T, et al
    EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer.
    Eur Urol. 2024 Apr 29:S0302-2838(24)02306-6. doi: 10.1016/j.eururo.2024.
    >> Share

  93. OST P, Siva S, Zilli T
    OLIGOPELVIS and the "All You Can Eat" Strategy for Oligorecurrent Nodal Prostate Cancer: Are We Already Full?
    Eur Urol. 2024 Apr 27:S0302-2838(24)02307-8. doi: 10.1016/j.eururo.2024.
    >> Share

  94. HU JC, Vickers AJ, Schaeffer EM
    Reply to Peter Ka-Fung Chiu, Xiaobo Wu, Giorgio Gandaglia, European Association of Urology Young Academic Urologists Prostate Cancer Working Party. Beyond Statistical Significance: Unveiling the Advantages of Transperineal Versus Transrectal Prostate
    Eur Urol. 2024 Apr 26:S0302-2838(24)02314-5. doi: 10.1016/j.eururo.2024.
    >> Share

  95. CHAKRABARTI D, Parker CC
    Metastatic Hormone-sensitive Prostate Cancer: Patient Selection for Prostate Radiotherapy.
    Eur Urol. 2024 Apr 26:S0302-2838(24)02308-X. doi: 10.1016/j.eururo.2024.
    >> Share

  96. SAAD F, Hussain MHA, Tombal B, Fizazi K, et al
    Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of
    Eur Urol. 2024 Apr 20:S0302-2838(24)02264-4. doi: 10.1016/j.eururo.2024.
    >> Share

  97. HINDIE E, Champion C, Morgat C
    Re: Renu S. Eapen, James P. Buteau, Price Jackson, et al. Administering [(177)Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study. Eur Urol. In press.
    Eur Urol. 2024 Apr 20:S0302-2838(24)02310-8. doi: 10.1016/j.eururo.2024.
    >> Share

  98. CARDONA ORTEGON JD, Campana Perilla LA, Olarte Bermudez LM
    Re: Matthias Boschheidgen, Peter Albers, Heinz-Peter Schlemmer, et al. Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial. Eur Urol 2024;85:105-11
    Eur Urol. 2024 Apr 20:S0302-2838(24)02315-7. doi: 10.1016/j.eururo.2024.
    >> Share

  99. CORNFORD P, van den Bergh RCN, Briers E, Van den Broeck T, et al
    EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent.
    Eur Urol. 2024 Apr 12:S0302-2838(24)02254-1. doi: 10.1016/j.eururo.2024.
    >> Share

  100. GRABBERT M, Liakos N, Gratzke C
    Re: Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer.
    Eur Urol. 2024 Apr 11:S0302-2838(24)02258-9. doi: 10.1016/j.eururo.2024.
    >> Share

  101. RUSH HL, Gilbert DC, Langley RE
    Re: Bertrand Tombal, Sean Collins, Alicia K. Morgans, et al. Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study. Eur Urol 2023;84:579-87.
    Eur Urol. 2024 Apr 6:S0302-2838(24)02251-6. doi: 10.1016/j.eururo.2024.
    >> Share

  102. ROY S, Fervaha G, Spratt DE, Sun Y, et al
    Prostate Radiotherapy in Low-volume Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis.
    Eur Urol. 2024 Apr 2:S0302-2838(24)02239-5. doi: 10.1016/j.eururo.2024.
    >> Share

  103. ROY S, Saad F, Malone S, Agarwal N, et al
    Effect of Prior Prostate Directed Local Therapy on Response to Apalutamide in Metastatic Hormone Sensitive Prostate Cancer: A Secondary Analysis of the TITAN Study.
    Eur Urol. 2024;85:398-400.
    >> Share

  104. O'CALLAGHAN M, Bulamu N, Gormly K, Jay A, et al
    Re: Prevalence of MRI Lesions in Men Responding to a GP-led Invitation for a Prostate Health Check: A Prospective Cohort Study.
    Eur Urol. 2024;85:395.
    >> Share

    March 2024
  105. ENGLMAN C, Maffei D, Allen C, Kirkham A, et al
    PRECISE Version 2: Updated Recommendations for Reporting Prostate Magnetic Resonance Imaging in Patients on Active Surveillance for Prostate Cancer.
    Eur Urol. 2024 Mar 30:S0302-2838(24)02232-2. doi: 10.1016/j.eururo.2024.
    >> Share

  106. LOGOTHETIS CJ, Hahn AW
    Reply to Richard J. Wassersug, Paul F. Schellhammer, and Erik Wibowo's Letter to the Editor re: Christoper J. Logothetis, Andrew W. Hahn. Challenging the Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap Syndrome. Eur Urol 2024
    Eur Urol. 2024 Mar 26:S0302-2838(24)02240-1. doi: 10.1016/j.eururo.2024.
    >> Share

  107. WASSERSUG RJ, Schellhammer PF, Wibowo E
    Re: Christoper J. Logothetis, Andrew W. Hahn. Challenging the Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap Syndrome. Eur Urol 2024;85:3-7.
    Eur Urol. 2024 Mar 26:S0302-2838(24)02233-4. doi: 10.1016/j.eururo.2024.
    >> Share

  108. WINDISCH O, Valerio M
    Re: Evaluation of Outcomes Following Focal Ablative Therapy for Treatment of Localised Clinically Significant Prostate Cancer in Patients >70 Years: A Multi-institute, Multi-energy 15-year Experience.
    Eur Urol. 2024 Mar 26:S0302-2838(24)02208-5. doi: 10.1016/j.eururo.2024.
    >> Share

  109. DE MEERLEER G, Joniau S, Benijts J, Rans K, et al
    Oligometastatic Recurrent Prostate Cancer: Whether To Intensify Treatment or Not.
    Eur Urol. 2024 Mar 22:S0302-2838(24)02238-3. doi: 10.1016/j.eururo.2024.
    >> Share

  110. BURGER M
    Re: First-in-human Evaluation of a Prostate-specific Membrane Antigen-targeted Near-infrared Fluorescent Small Molecule for Fluorescence-based Identification of Prostate Cancer in Patients with High-risk Prostate Cancer Undergoing Robotic-assisted Pro
    Eur Urol. 2024 Mar 22:S0302-2838(24)02205-X. doi: 10.1016/j.eururo.2024.
    >> Share

  111. NIKITAS J, Rettig M, Shen J, Reiter R, et al
    Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical Trial.
    Eur Urol. 2024 Mar 16:S0302-2838(24)00058-7. doi: 10.1016/j.eururo.2024.
    >> Share

  112. BABOUDJIAN M, Diamand R, Uleri A, Beauval JB, et al
    Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment?
    Eur Urol. 2024 Mar 16:S0302-2838(24)00071-X. doi: 10.1016/j.eururo.2024.
    >> Share

  113. CUSSENOT O, Chambaz A, Hamdy FC
    Re: Annika Herlemann, Janet E. Cowan, Samuel L. Washington 3rd, et al. Long-term Prostate Cancer-specific Mortality After Prostatectomy, Brachytherapy, External Beam Radiation Therapy, Hormonal Therapy, or Monitoring for Localized Prostate Cancer. Eur
    Eur Urol. 2024 Mar 15:S0302-2838(24)02139-0. doi: 10.1016/j.eururo.2024.
    >> Share

  114. GARCIA-RUIZ A, Macarro C, Zacchi F, Morales-Barrera R, et al
    Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castration-resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical Trial.
    Eur Urol. 2024 Mar 14:S0302-2838(24)02133-X. doi: 10.1016/j.eururo.2024.
    >> Share

  115. MOLLER F, Mansson M, Wallstrom J, Hellstrom M, et al
    Prostate Cancers in the Prostate-specific Antigen Interval of 1.8-3 ng/ml: Results from the Goteborg-2 Prostate Cancer Screening Trial.
    Eur Urol. 2024 Mar 14:S0302-2838(24)00052-6. doi: 10.1016/j.eururo.2024.
    >> Share

  116. WEBER M, Fendler WP, Ravi Kumar AS, Calais J, et al
    Prostate-specific Membrane Antigen Positron Emission Tomography-detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study.
    Eur Urol. 2024 Mar 14:S0302-2838(24)00054-X. doi: 10.1016/j.eururo.2024.
    >> Share

  117. VAUGIER L, Morvan C, Pasquier D, Buthaud X, et al
    Long-term Outcomes and Patterns of Relapse Following High-dose Elective Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Nodes in Prostate Cancer: OLIGOPELVIS (GETUG-P07).
    Eur Urol. 2024 Mar 14:S0302-2838(24)02131-6. doi: 10.1016/j.eururo.2024.
    >> Share

  118. NICKOLS NG, Tsai S, Kane N, Tran S, et al
    Systemic and Tumor-directed Therapy for Oligometastatic Prostate Cancer: The SOLAR Phase 2 Trial in De Novo Oligometastatic Prostate Cancer.
    Eur Urol. 2024 Mar 14:S0302-2838(24)00079-4. doi: 10.1016/j.eururo.2024.
    >> Share

  119. MONTIRONI R, Cimadamore A, Giannarini G, Crestani A, et al
    Re: Outcomes of Biopsy Grade Group 1 Prostate Cancer Diagnosis in the Danish Population.
    Eur Urol. 2024 Mar 14:S0302-2838(24)02141-9. doi: 10.1016/j.eururo.2024.
    >> Share

  120. FODOR A, Brombin C, Chiti A, Di Muzio N, et al
    Re: Marcin Miszczyk, Pawel Rajawa, Takafumi Yanagisawa, et al. The Efficacy and Safety of Metastasis-directed Therapy in Patients with Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies. Eur Urol. In press. https://doi.org/1
    Eur Urol. 2024 Mar 12:S0302-2838(24)02140-7. doi: 10.1016/j.eururo.2024.
    >> Share

  121. SARTOR O
    Prostate-specific Membrane Antigen-targeted Isotope Therapy: Inherent Challenges Owing to Heterogeneity and Clonal Evolution.
    Eur Urol. 2024;85:205-206.
    >> Share

  122. PILATZ A, MacLennan S, van den Bergh RCN, Veeratterapillay R, et al
    Reply to Badar M. Mian. Prostate Biopsy: Hyperbole and Misrepresentation Versus Scientific Evidence and Equipoise. Eur Urol. 2024;85:99-100.
    Eur Urol. 2024;85:313-314.
    >> Share

    February 2024
  123. GOLIJANIN B, Mega A, Golijanin D
    Re: Ivo I. de Vos II, Sebastiaan Remmers, Renee Hogenhout, Monique J. Roobol, ERSPC Rotterdam Study Group. Prostate Cancer Mortality Among Elderly Men After Discontinuing Organised Screening: Long-term Results from the European Randomized Study of Scr
    Eur Urol. 2024 Feb 29:S0302-2838(24)00081-2. doi: 10.1016/j.eururo.2024.
    >> Share

  124. POPE B, Park G, Lau E, Belic J, et al
    Ultrasensitive Detection of Circulating Tumour DNA enriches for Patients with a Greater Risk of Recurrence of Clinically Localised Prostate Cancer.
    Eur Urol. 2024 Feb 19:S0302-2838(24)00003-4. doi: 10.1016/j.eururo.2024.
    >> Share

  125. FENG D, Wang J, Wu R, Li D, et al
    Re: Immune System and Intestinal Microbiota Determine Efficacy of Androgen Deprivation Therapy Against Prostate Cancer.
    Eur Urol. 2024 Feb 17:S0302-2838(24)00069-1. doi: 10.1016/j.eururo.2024.
    >> Share

  126. DE VOS II, Remmers S, Roobol MJ
    Reply to Borivoj Golijanin, Anthony Mega, and Dragan Golijanin's Letter to the Editor re: Ivo I. de Vos, Sebastiaan Remmers, Renee Hogenhout, Monique J. Roobol, ERSPC Rotterdam Study Group. Prostate Cancer Mortality Among Elderly Men After Discontinui
    Eur Urol. 2024 Feb 17:S0302-2838(24)00057-5. doi: 10.1016/j.eururo.2024.
    >> Share

  127. DEIVASIGAMANI S, Kotamarti S, Gupta RT, Polascik TJ, et al
    Re: Low Cancer Yield in PI-RADS 3 Upgraded to 4 by Dynamic Contrast-enhanced MRI: Is It Time To Reconsider Scoring Categorization?
    Eur Urol. 2024;85:180-181.
    >> Share

  128. PREISSER F, Abrams-Pompe RS, Stelwagen PJ, Bohmer D, et al
    European Association of Urology Biochemical Recurrence Risk Classification as a Decision Tool for Salvage Radiotherapy-A Multicenter Study.
    Eur Urol. 2024;85:164-170.
    >> Share

  129. MIAN BM
    Prostate Biopsy: Hyperbole and Misrepresentation Versus Scientific Evidence and Equipoise.
    Eur Urol. 2024;85:99-100.
    >> Share

    January 2024
  130. ARMSTRONG WR, Kishan AU, Booker KM, Grogan TR, et al
    Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774).
    Eur Urol. 2024 Jan 29:S0302-2838(24)00013-7. doi: 10.1016/j.eururo.2024.
    >> Share

  131. VICKERS AJ, Assel M, Cooperberg MR, Fine SW, et al
    Amount of Gleason Pattern 3 Is Not Predictive of Risk in Grade Group 2-4 Prostate Cancer.
    Eur Urol. 2024 Jan 25:S0302-2838(24)00007-1. doi: 10.1016/j.eururo.2024.
    >> Share

  132. CHI KN, Armstrong AJ, Krause BJ, Herrmann K, et al
    Safety Analyses of the Phase 3 VISION Trial of [(177)Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2024 Jan 6:S0302-2838(23)03297-9. doi: 10.1016/j.eururo.2023.
    >> Share

    December 2023
  133. LIU M, Chen P, Li T
    Re: Fred Saad, Noel W. Clarke, Mototsugu Oya, et al. Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-blind, Phas
    Eur Urol. 2023 Dec 21:S0302-2838(23)03293-1. doi: 10.1016/j.eururo.2023.
    >> Share

  134. HUANG TB, Ding XF
    Re: Matthias Boschheidgen, Peter Albers, Heinz-Peter Schlemmer, et al. Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial, Eur Urol. In press. htt
    Eur Urol. 2023 Dec 16:S0302-2838(23)03294-3. doi: 10.1016/j.eururo.2023.
    >> Share

  135. ALBERS P, van Poppel H
    Prostate Cancer Screening at its Best: The Swedish Organized Prostate Cancer Testing Program.
    Eur Urol. 2023 Dec 15:S0302-2838(23)03290-6. doi: 10.1016/j.eururo.2023.
    >> Share

  136. CORPETTI M, Muller C, Beltran H, de Bono J, et al
    Prostate-Specific Membrane Antigen-Targeted Therapies for Prostate Cancer: Towards Improving Therapeutic Outcomes.
    Eur Urol. 2023 Dec 15:S0302-2838(23)03278-5. doi: 10.1016/j.eururo.2023.
    >> Share

  137. FERNANDEZ-ZAPATA WF, Gandur Quiroga MN, Cardona Maya WD
    Re: Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.
    Eur Urol. 2023 Dec 11:S0302-2838(23)03283-9. doi: 10.1016/j.eururo.2023.
    >> Share

  138. RAGGI D, Cigliola A, Mercinelli C, Patane D, et al
    Re: Which Patients with Metastatic Hormone-sensitive Prostate Cancer Benefit from Docetaxel: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Trials.
    Eur Urol. 2023 Dec 11:S0302-2838(23)03260-8. doi: 10.1016/j.eururo.2023.
    >> Share

  139. KAPLAN-MARANS E, Zhang TR, Hu JC
    Reply to Fabian Falkenbach, Francesco Sanguedolce, and Lars Budaus's Letter to the Editor re: Elie Kaplan-Marans, Tenny R. Zhang, Jim C. Hu. Differing Recommendations on Prostate Biopsy Approach to Minimize Infections: An Examination of the European A
    Eur Urol. 2023;84:e151.
    >> Share

  140. CAPOGROSSO P, Deho F, Salonia A, Briganti A, et al
    Re: Jean-Nicolas Cornu, Paul Zantek, Glyn Burtt, et al. Minimally Invasive Treatments for Benign Prostatic Obstruction: A Systematic Review and Network Meta-analysis. Eur Urol 2023;83:534-47.
    Eur Urol. 2023;84:e146.
    >> Share

  141. DJAILEB L, Armstrong WR, Thompson D, Gafita A, et al
    Presurgical (68)Ga-PSMA-11 Positron Emission Tomography for Biochemical Recurrence Risk Assessment: A Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging Trial.
    Eur Urol. 2023;84:588-596.
    >> Share

  142. SAAD F, Del Rosario P, Clarke NW
    Reply to Lin Ding, Bin Yang, and Xudong Yao's Letter to the Editor re: Fred Saad, Noel W. Clarke, Mototsugu Oya, et al. Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-resistant Prostate Cancer (PROpel): Final Prespe
    Eur Urol. 2023 Dec 1:S0302-2838(23)03274-8. doi: 10.1016/j.eururo.2023.
    >> Share

  143. BRATT O, Godtman RA, Jiborn T, Wallstrom J, et al
    Population-based Organised Prostate Cancer Testing: Results from the First Invitation of 50-year-old Men.
    Eur Urol. 2023 Dec 1:S0302-2838(23)03272-4. doi: 10.1016/j.eururo.2023.
    >> Share

  144. FALKENBACH F, Sanguedolce F, Budaus L
    Re: Elie Kaplan-Marans, Tenny R. Zhang, Jim C. Hu. Differing Recommendations on Prostate Biopsy Approach to Minimize Infections: An Examination of the European Association of Urology and American Urological Association Guidelines. Eur Urol. 2023;84:44
    Eur Urol. 2023;84:e149-e150.
    >> Share

    November 2023
  145. GIESEN A, Devlies W, Claessens F, Joniau S, et al
    Re: Abiraterone and Olaparib for Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2023 Nov 27:S0302-2838(23)03273-6. doi: 10.1016/j.eururo.2023.
    >> Share

  146. DING L, Yang B, Yao X
    Re: Fred Saad, Noel W. Clarke, Mototsugu Oya, et al. Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-blind, Phas
    Eur Urol. 2023 Nov 23:S0302-2838(23)03226-8. doi: 10.1016/j.eururo.2023.
    >> Share

  147. MUN CHOW K, Zheng So W, Jie Lee H, Lee A, et al
    Corrigendum to "Head-to-head Comparison of the Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography and Conventional Imaging Modalities for Initial Staging of Intermediate- to High-risk Prostate Cancer: A Systematic R
    Eur Urol. 2023 Nov 14:S0302-2838(23)03213-X. doi: 10.1016/j.eururo.2023.
    >> Share

  148. MOORE CM, Albertsen P
    When Is It Too Early To Start Prostate Cancer Screening? Reflections on the PROBASE Study Using Magnetic Resonance Imaging for Men Aged 45 Yr with Elevated Prostate-specific Antigen.
    Eur Urol. 2023 Nov 13:S0302-2838(23)03212-8. doi: 10.1016/j.eururo.2023.
    >> Share

  149. HAMDY FC, Donovan JL
    Reply to Greg Shaw, John D. Kelly, and Monique J. Roobol's Letter to the Editor re: Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, et al. Fifteen-Year Outcomes After Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023;388:
    Eur Urol. 2023 Nov 8:S0302-2838(23)03218-9. doi: 10.1016/j.eururo.2023.
    >> Share

  150. MISZCZYK M, Rajwa P, Yanagisawa T, Nowicka Z, et al
    The Efficacy and Safety of Metastasis-directed Therapy in Patients with Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies.
    Eur Urol. 2023 Nov 7:S0302-2838(23)03209-8. doi: 10.1016/j.eururo.2023.
    >> Share

  151. TRUJILLO CG, Pena Rodriguez S, Diaz Ritter C
    Re: Jean-Nicolas Cornu, Paul Zantek, Glyn Burtt, et al. Minimally Invasive Treatments for Benign Prostatic Obstruction: A Systematic Review and Network Meta-analysis. Eur Urol. 2023;83:534-47.
    Eur Urol. 2023;84:e116.
    >> Share

  152. FENG T, Ren M, Zhou Z
    Re: Peter Fletcher, Marta De Santis, Simona Ippoliti, et al. Vector Prostate Biopsy: A Novel Magnetic Resonance Imaging/Ultrasound Image Fusion Transperineal Biopsy Technique Using Electromagnetic Needle Tracking Under Local Anaesthesia. Eur Urol 2023
    Eur Urol. 2023;84:e114.
    >> Share

  153. LINDER S, Severson TM, van der Mijn KJC, Nevedomskaya E, et al
    Grade Group 1 Prostate Cancers Exhibit Tumor-defining Androgen Receptor-driven Programs.
    Eur Urol. 2023;84:455-460.
    >> Share

  154. WERNER RA, Hartrampf PE, Fendler WP, Serfling SE, et al
    Prostate-specific Membrane Antigen Reporting and Data System Version 2.0.
    Eur Urol. 2023;84:491-502.
    >> Share

    October 2023
  155. DE VOS II, Remmers S, Hogenhout R, Roobol MJ, et al
    Prostate Cancer Mortality Among Elderly Men After Discontinuing Organised Screening: Long-term Results from the European Randomized Study of Screening for Prostate Cancer Rotterdam.
    Eur Urol. 2023 Oct 31:S0302-2838(23)03207-4. doi: 10.1016/j.eururo.2023.
    >> Share

  156. SHAW G, Kelly JD, Roobol MJ
    Re: Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, et al. Fifteen-Year Outcomes After Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023;388:1547-58.
    Eur Urol. 2023 Oct 26:S0302-2838(23)03170-6. doi: 10.1016/j.eururo.2023.
    >> Share

  157. EAPEN RS, Buteau JP, Jackson P, Mitchell C, et al
    Administering [(177)Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study.
    Eur Urol. 2023 Oct 25:S0302-2838(23)03087-7. doi: 10.1016/j.eururo.2023.
    >> Share

  158. SHARMA AD, Good DW, Alan McNeill S
    Re: Patient-reported Outcomes 12 Years after Localized Prostate Cancer Treatment.
    Eur Urol. 2023 Oct 19:S0302-2838(23)03157-3. doi: 10.1016/j.eururo.2023.
    >> Share

  159. BOSCHHEIDGEN M, Albers P, Schlemmer HP, Hellms S, et al
    Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial.
    Eur Urol. 2023 Oct 18:S0302-2838(23)03158-5. doi: 10.1016/j.eururo.2023.
    >> Share

  160. HERLEMANN A, Cowan JE, Washington SL 3rd, Wong AC, et al
    Long-term Prostate Cancer-specific Mortality After Prostatectomy, Brachytherapy, External Beam Radiation Therapy, Hormonal Therapy, or Monitoring for Localized Prostate Cancer.
    Eur Urol. 2023 Oct 17:S0302-2838(23)03155-X. doi: 10.1016/j.eururo.2023.
    >> Share

  161. SORCE G, Mottrie A
    Re: Unilateral Pelvic Lymph Node Dissection in Prostate Cancer Patients Diagnosed in the Era of Magnetic Resonance Imaging-targeted Biopsy: A Study that Challenges the Dogma.
    Eur Urol. 2023 Oct 14:S0302-2838(23)03159-7. doi: 10.1016/j.eururo.2023.
    >> Share

  162. GANDAGLIA G, Barletta F, Briganti A, Montorsi F, et al
    Re: Laura Bukavina, Amy N. Luckenbaugh, Michael S. Hofman, et al. Incorporating Prostate-specific Membrane Antigen Positron Emission Tomography in Management Decisions for Men with Newly Diagnosed or Biochemically Recurrent Prostate Cancer. Eur Urol 2
    Eur Urol. 2023 Oct 11:S0302-2838(23)03140-8. doi: 10.1016/j.eururo.2023.
    >> Share

  163. KRAFFT U, Hadaschik BA, Luckerath K, Herrmann K, et al
    A New Chapter in Neoadjuvant Therapy for High-risk Prostate Cancer?
    Eur Urol. 2023 Oct 11:S0302-2838(23)03149-4. doi: 10.1016/j.eururo.2023.
    >> Share

  164. TOMBAL B, Collins S, Morgans AK, Hunsche E, et al
    Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study.
    Eur Urol. 2023 Oct 11:S0302-2838(23)03099-3. doi: 10.1016/j.eururo.2023.
    >> Share

  165. JUNG J, Kim JH
    Re: Casey Crump, Par Stattin, James D. Brooks, et al. Long-term Risks of Depression and Suicide Among Men with Prostate Cancer: A National Cohort Study. Eur Urol 2023;84:263-72.
    Eur Urol. 2023 Oct 11:S0302-2838(23)03154-8. doi: 10.1016/j.eururo.2023.
    >> Share

  166. HICKS RJ
    The Pythia Speaks on Prostate Cancer Diagnosis and Treatment.
    Eur Urol. 2023 Oct 11:S0302-2838(23)03148-2. doi: 10.1016/j.eururo.2023.
    >> Share

  167. KISHAN AU, Valle LF, Marks LS
    Bullseye or Tip of the Iceberg: Magnetic Resonance Imaging-visible Disease in Radiorecurrent Prostate Cancer.
    Eur Urol. 2023 Oct 5:S0302-2838(23)03145-7. doi: 10.1016/j.eururo.2023.
    >> Share

  168. COLE AP, Gupta N, Loeb S
    The Plant-based Prescription: How Dietary Change Can Improve Both Urological and Planetary Health.
    Eur Urol. 2023;84:357-358.
    >> Share

  169. HEIJNSDIJK EAM, de Koning HJ
    Wise Prostate-specific Antigen Testing Means a Limited, Risk-adjusted, and Personal Approach.
    Eur Urol. 2023;84:359-360.
    >> Share

    September 2023
  170. LIGHT A, Kanthabalan A, Otieno M, Pavlou M, et al
    The Role of Multiparametric MRI and MRI-targeted Biopsy in the Diagnosis of Radiorecurrent Prostate Cancer: An Analysis from the FORECAST Trial.
    Eur Urol. 2023 Sep 29:S0302-2838(23)03089-0. doi: 10.1016/j.eururo.2023.
    >> Share

  171. LAMBERT E, Roupret M
    Re: Niraparib and Abiraterone Acetate for Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2023 Sep 27:S0302-2838(23)03137-8. doi: 10.1016/j.eururo.2023.
    >> Share

  172. BEATRICI E, Labban M, Stone BV, Filipas DK, et al
    Uncovering the Changing Treatment Landscape for Low-risk Prostate Cancer in the USA from 2010 to 2020: Insights from the National Cancer Data Base.
    Eur Urol. 2023 Sep 25:S0302-2838(23)03088-9. doi: 10.1016/j.eururo.2023.
    >> Share

  173. PONTES-SILVA A
    Re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial. Eur Urol 2023
    Eur Urol. 2023 Sep 25:S0302-2838(23)03094-4. doi: 10.1016/j.eururo.2023.
    >> Share

  174. ILIE G, Rutledge RDH
    Reply to Andre Pontes-Silva's Letter to the Editor re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Tr
    Eur Urol. 2023 Sep 22:S0302-2838(23)03091-9. doi: 10.1016/j.eururo.2023.
    >> Share

  175. MAY M, Wolff I, Brookman-May SD
    Re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial. Eur Urol 2023
    Eur Urol. 2023 Sep 22:S0302-2838(23)03095-6. doi: 10.1016/j.eururo.2023.
    >> Share

  176. KLOTZ L
    Re: MRI-Detectability of Clinically Significant Prostate Cancer Relates to Oncologic Outcomes After Prostatectomy.
    Eur Urol. 2023 Sep 22:S0302-2838(23)03080-4. doi: 10.1016/j.eururo.2023.
    >> Share

  177. OPREA-LAGER DE, MacLennan S, Bjartell A, Briganti A, et al
    European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer.
    Eur Urol. 2023 Sep 22:S0302-2838(23)03092-0. doi: 10.1016/j.eururo.2023.
    >> Share

  178. ILIE G, Rutledge RDH
    Reply to Matthias May, Ingmar Wolff, and Sabine D. Brookman-May's Letter to the Editor re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Un
    Eur Urol. 2023 Sep 22:S0302-2838(23)03093-2. doi: 10.1016/j.eururo.2023.
    >> Share

  179. VAN POPPEL H, Roobol MJ, Chandran A
    Early Detection of Prostate Cancer in the European Union: Combining Forces with PRAISE-U.
    Eur Urol. 2023 Sep 11:S0302-2838(23)03023-3. doi: 10.1016/j.eururo.2023.
    >> Share

  180. MICHEL MC
    Re: Genetically Adjusted PSA Levels for Prostate Cancer Screening.
    Eur Urol. 2023 Sep 9:S0302-2838(23)03081-6. doi: 10.1016/j.eururo.2023.
    >> Share

  181. ROCCO B, Sighinolfi MC
    Re: Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023; 388:1547-58.
    Eur Urol. 2023 Sep 6:S0302-2838(23)03069-5. doi: 10.1016/j.eururo.2023.
    >> Share

    August 2023
  182. PAPACHRISTODOULOU A, Heidegger I, Virk RK, Di Bernardo M, et al
    Metformin Overcomes the Consequences of NKX3.1 Loss to Suppress Prostate Cancer Progression.
    Eur Urol. 2023 Aug 31:S0302-2838(23)03016-6. doi: 10.1016/j.eururo.2023.
    >> Share

  183. HAMDY FC, Donovan JL
    Reply to Bernardo Rocco and Maria Chiara Sighinolfi's Letter to the Editor re: Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023;388:1547-
    Eur Urol. 2023 Aug 31:S0302-2838(23)03070-1. doi: 10.1016/j.eururo.2023.
    >> Share

  184. LUPOLD SE, Isaacs WB, Luo J
    Aggravated Androgen Receptor Activity in Otherwise Indolent Prostate Cancer.
    Eur Urol. 2023 Aug 25:S0302-2838(23)03028-2. doi: 10.1016/j.eururo.2023.
    >> Share

  185. ROY S, Sun Y, Morgan S, Malone S, et al
    Reply to Xiao Li, Zicheng Xu, and Feng Qi's Letter to the Editor re: Soumyajit Roy, Yilun Sun, Scott C. Morgan, et al. Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis Targeted Therapy in Metastatic Castrate-resistant Pro
    Eur Urol. 2023 Aug 16:S0302-2838(23)03021-X. doi: 10.1016/j.eururo.2023.
    >> Share

  186. LI X, Xu Z, Qi F
    Re: Soumyajit Roy, Yilun Sun, Scott C. Morgan, et al. Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis Targeted Therapy in Metastatic Castrate-resistant Prostate Cancer: A Secondary Analysis of the COU-AA-302 Trial. Eur U
    Eur Urol. 2023 Aug 16:S0302-2838(23)03022-1. doi: 10.1016/j.eururo.2023.
    >> Share

  187. GRAVAS S, Gacci M, Gratzke C, Herrmann TRW, et al
    Summary Paper on the 2023 European Association of Urology Guidelines on the Management of Non-neurogenic Male Lower Urinary Tract Symptoms.
    Eur Urol. 2023;84:207-222.
    >> Share

  188. CHIU PK, Kasivisvanathan V, Gandaglia G
    Moving the Needle: Antibiotic Prophylaxis Is No Longer Required in the Era of Transperineal Prostate Biopsy.
    Eur Urol. 2023;84:154-155.
    >> Share

    July 2023
  189. POULIOT F, Emmett L
    Prostate-specific Membrane Antigen Imaging Remains True to its Name in Primary Staging of Prostate Cancer: The Time To Characterize its Impact on Clinical Outcomes Is Now.
    Eur Urol. 2023 Jul 28:S0302-2838(23)02974-3. doi: 10.1016/j.eururo.2023.
    >> Share

  190. WANG M, Wittenberg S, Cher ML, Van Til M, et al
    Does Urologist-level Utilization of Active Surveillance for Low-risk Prostate Cancer Correspond with Utilization of Active Surveillance for Small Renal Masses?
    Eur Urol. 2023 Jul 26:S0302-2838(23)02973-1. doi: 10.1016/j.eururo.2023.
    >> Share

  191. LAURITZEN PM, Jacewitz M, Baco E, Rud E, et al
    Re: Peter Ka-Fung Chiu, Veeru Kasivisvanathan, Giorgio Gandaglia, European Association of Urology Young Academic Urologists Prostate Cancer Working Party. Moving the Needle: Antibiotic Prophylaxis Is No Longer Required in the Era of Transperineal Pros
    Eur Urol. 2023 Jul 21:S0302-2838(23)02958-5. doi: 10.1016/j.eururo.2023.
    >> Share

  192. BOESEN L
    Re: Best Current Practice and Research Priorities in Active Surveillance for Prostate Cancer-A Report of a Movember International Consensus Meeting.
    Eur Urol. 2023 Jul 19:S0302-2838(23)02967-6. doi: 10.1016/j.eururo.2023.
    >> Share

  193. JIA AY, Kishan AU, Spratt DE
    Re: Dose-escalated Radiotherapy Alone or in Combination with Short-term Androgen Deprivation for Intermediate-risk Prostate Cancer: Results of a Phase III Multi-institutional Trial.
    Eur Urol. 2023 Jul 11:S0302-2838(23)02964-0. doi: 10.1016/j.eururo.2023.
    >> Share

  194. DEIVASIGAMANI S, Kotamarti S, Rastinehad AR, Salas RS, et al
    Primary Whole-gland Ablation for the Treatment of Clinically Localized Prostate Cancer: A Focal Therapy Society Best Practice Statement.
    Eur Urol. 2023 Jul 5:S0302-2838(23)02943-3. doi: 10.1016/j.eururo.2023.
    >> Share

  195. GANDAGLIA G, Pellegrino F, Golozar A, De Meulder B, et al
    Clinical Characterization of Patients Diagnosed with Prostate Cancer and Undergoing Conservative Management: A PIONEER Analysis Based on Big Data.
    Eur Urol. 2023 Jul 4:S0302-2838(23)02944-5. doi: 10.1016/j.eururo.2023.
    >> Share

  196. SURASI DS, Eiber M, Maurer T, Preston MA, et al
    Diagnostic Performance and Safety of Positron Emission Tomography with (18)F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE).
    Eur Urol. 2023 Jul 4:S0302-2838(23)02949-4. doi: 10.1016/j.eururo.2023.
    >> Share

  197. DAZA F, Diaz Ritter C, Badillo N
    Re: Michael S. Leapman, Cassandra L. Thiel, Ilyssa O. Gordon, et al. Environmental Impact of Prostate Magnetic Resonance Imaging and Transrectal Ultrasound Guided Prostate Biopsy. Eur Urol. 2023;83:463-71.
    Eur Urol. 2023;84:e12.
    >> Share

  198. SCHAFER EJ, Jemal A, Wiese D, Sung H, et al
    Disparities and Trends in Genitourinary Cancer Incidence and Mortality in the USA.
    Eur Urol. 2023;84:117-126.
    >> Share

    June 2023
  199. FENG F, Miladinovic B, Zhang K, Dignam JJ, et al
    Early Endpoints in High-risk Localized Prostate Cancer: Exploratory Analysis of Three Radiation Therapy Oncology Group Phase 3 Studies.
    Eur Urol. 2023 Jun 29:S0302-2838(23)02876-2. doi: 10.1016/j.eururo.2023.
    >> Share

  200. ARDOLINO LC, Dear R, Armstrong AJ, Gillessen S, et al
    Re: Timothee Olivier, Kerrington Powell, Vinay Prasad. Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial. Eur Urol. 2023;84:4-6.
    Eur Urol. 2023 Jun 22:S0302-2838(23)02893-2. doi: 10.1016/j.eururo.2023.
    >> Share

  201. NGUYEN DD, Satkunasivam R, Wallis CJD
    Tackling Depression and Suicide Among Prostate Cancer Survivors: From Clinical Innovations to Continued Advocacy on the Upstream Social Determinants of Health.
    Eur Urol. 2023 Jun 21:S0302-2838(23)02891-9. doi: 10.1016/j.eururo.2023.
    >> Share

  202. ABIDA W, Campbell D, Patnaik A, Bryce AH, et al
    Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study.
    Eur Urol. 2023 Jun 3:S0302-2838(23)02828-2. doi: 10.1016/j.eururo.2023.
    >> Share

  203. COLOMBA E, Jonas SF, Eymard JC, Delva R, et al
    A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA.
    Eur Urol. 2023 Jun 2:S0302-2838(23)02814-2. doi: 10.1016/j.eururo.2023.
    >> Share

  204. VAN DEN BROECK T, Joniau S, Everaerts W
    Adjuvant Docetaxel in Nonmetastatic Prostate Cancer: The King Is Dead, Long Live the King!
    Eur Urol. 2023 Jun 1:S0302-2838(23)02879-8. doi: 10.1016/j.eururo.2023.
    >> Share

    May 2023
  205. CHANG D, Appu S, Siva S
    Re: Fifteen-Year Outcomes After Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
    Eur Urol. 2023 May 31:S0302-2838(23)02832-4. doi: 10.1016/j.eururo.2023.
    >> Share

  206. JIANG T, Valle LF, Kishan AU
    Contemporary Evaluation of Salvage Radiotherapy for Prostate Cancer: Radiotherapy Dose, Field Size, and Use of Hormone Therapy.
    Eur Urol. 2023 May 26:S0302-2838(23)02817-8. doi: 10.1016/j.eururo.2023.
    >> Share

  207. ILIE G, Rutledge RDH
    Reply to Zhipeng Mai, Weigang Yan, and Zhien Zhou's Letter to the Editor re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curat
    Eur Urol. 2023 May 26:S0302-2838(23)02820-8. doi: 10.1016/j.eururo.2023.
    >> Share

  208. MAI Z, Yan W, Zhou Z
    Re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial. Eur Urol. 202
    Eur Urol. 2023 May 26:S0302-2838(23)02821-X. doi: 10.1016/j.eururo.2023.
    >> Share

  209. GONZALEZ-PADILLA DA, Subiela JD
    Are PARP Inhibitors Ready for Prime Time in Metastatic Prostate Cancer? Maybe Not.
    Eur Urol. 2023 May 25:S0302-2838(23)02824-5. doi: 10.1016/j.eururo.2023.
    >> Share

  210. LOGOTHETIS CJ, Hahn AW
    Challenging the Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap Syndrome.
    Eur Urol. 2023 May 18:S0302-2838(23)02776-8. doi: 10.1016/j.eururo.2023.
    >> Share

  211. COOPERBERG MR
    Re: Fifteen-year Outcomes After Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
    Eur Urol. 2023 May 17:S0302-2838(23)02805-1. doi: 10.1016/j.eururo.2023.
    >> Share

  212. JUNG J, Kim JH
    Re: Loren K. Mell, Stephanie L. Pugh, Christopher U. Jones, et al. Effects of Androgen Deprivation Therapy on Prostate Cancer Outcomes According to Competing Event Risk: Secondary Analysis of a Phase 3 Randomised Trial. Eur Urol. In press. https://doi
    Eur Urol. 2023 May 16:S0302-2838(23)02807-5. doi: 10.1016/j.eururo.2023.
    >> Share

  213. BERGENGREN O, Pekala KR, Matsoukas K, Fainberg J, et al
    2022 Update on Prostate Cancer Epidemiology and Risk Factors-A Systematic Review.
    Eur Urol. 2023 May 16:S0302-2838(23)02786-0. doi: 10.1016/j.eururo.2023.
    >> Share

  214. MAJUMDAR JR, Carlsson SV
    Re: A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial.
    Eur Urol. 2023 May 13:S0302-2838(23)02796-3. doi: 10.1016/j.eururo.2023.
    >> Share

  215. GHAMANDE SS, Klaassen Z, Wallis CJD
    Re: Darolutamide plus Androgen-deprivation Therapy and Docetaxel in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial.
    Eur Urol. 2023 May 12:S0302-2838(23)02794-X. doi: 10.1016/j.eururo.2023.
    >> Share

  216. SARTOR O, Karrison TG, Sandler HM, Gomella LG, et al
    Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial.
    Eur Urol. 2023 May 11:S0302-2838(23)02788-4. doi: 10.1016/j.eururo.2023.
    >> Share

  217. ARMSTRONG AJ, Iguchi T, Azad AA, Villers A, et al
    The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES.
    Eur Urol. 2023 May 11:S0302-2838(23)02723-9. doi: 10.1016/j.eururo.2023.
    >> Share

  218. SJOSTROM M, Bjartell A
    Re: Niraparib and Abiraterone Acetate for Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2023 May 11:S0302-2838(23)02793-8. doi: 10.1016/j.eururo.2023.
    >> Share

  219. SUTERA P, Song Y, Van der Eecken K, Shetty AC, et al
    Clinical and Genomic Differences Between Advanced Molecular Imaging-detected and Conventional Imaging-detected Metachronous Oligometastatic Castration-sensitive Prostate Cancer.
    Eur Urol. 2023 May 10:S0302-2838(23)02790-2. doi: 10.1016/j.eururo.2023.
    >> Share

  220. CRUMP C, Stattin P, Brooks JD, Sundquist J, et al
    Long-term Risks of Depression and Suicide Among Men with Prostate Cancer: A National Cohort Study.
    Eur Urol. 2023 May 9:S0302-2838(23)02787-2. doi: 10.1016/j.eururo.2023.
    >> Share

  221. BJERNER J, Bratt O, Aas K, Albertsen PC, et al
    Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death-Results from the Norwegian Prostate Cancer Consortium.
    Eur Urol. 2023 May 9:S0302-2838(23)02791-4. doi: 10.1016/j.eururo.2023.
    >> Share

  222. PLATA M, Cesar DR, Badillo N
    Re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial. Eur Urol. In
    Eur Urol. 2023 May 3:S0302-2838(23)02782-3. doi: 10.1016/j.eururo.2023.
    >> Share

  223. STRANNE J, Mottet N, Rouviere O
    Systematic Biopsies as a Complement to Magnetic Resonance Imaging-targeted Biopsies: "To Be or Not To Be"?
    Eur Urol. 2023;83:381-384.
    >> Share

  224. LEAPMAN MS, Thiel CL, Gordon IO, Nolte AC, et al
    Environmental Impact of Prostate Magnetic Resonance Imaging and Transrectal Ultrasound Guided Prostate Biopsy.
    Eur Urol. 2023;83:463-471.
    >> Share

  225. TERLIZZI M, Bossi A
    Re: The Addition of Androgen Deprivation Therapy and Pelvic Lymph Node Treatment to Prostate Bed Salvage Radiotherapy (NRG Oncology/RTOG 0534 SPPORT): An International, Multicentre, Randomised Phase 3 Trial.
    Eur Urol. 2023;83:475.
    >> Share

  226. SCHAFER H, Mayr S, Buttner-Herold M, Knorr K, et al
    Extensive (177)Lu-PSMA Radioligand Therapy Can Lead to Radiation Nephropathy with a Renal Thrombotic Microangiopathy-like Picture.
    Eur Urol. 2023;83:385-390.
    >> Share

    April 2023
  227. ILIE G, David Harold Rutledge R
    Reply to Mauricio Plata, Cesar Diaz Ritter, and Nicolas Badillo's Letter to the Editor re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Un
    Eur Urol. 2023 Apr 29:S0302-2838(23)02781-1. doi: 10.1016/j.eururo.2023.
    >> Share

  228. MARRA G, van Leenders GJLH, Zattoni F, Kesch C, et al
    Impact of Epithelial Histological Types, Subtypes, and Growth Patterns on Oncological Outcomes for Patients with Nonmetastatic Prostate Cancer Treated with Curative Intent: A Systematic Review.
    Eur Urol. 2023 Apr 27:S0302-2838(23)02654-4. doi: 10.1016/j.eururo.2023.
    >> Share

  229. SHARMA AD, Lopez JF, Leiblich A, Leslie TA, et al
    Re: Fifteen-year Outcomes After Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
    Eur Urol. 2023 Apr 26:S0302-2838(23)02712-4. doi: 10.1016/j.eururo.2023.
    >> Share

  230. SOH PXY, Hayes VM
    Common Genetic Variants Associated with Prostate Cancer Risk: The Need for African Inclusion.
    Eur Urol. 2023 Apr 24:S0302-2838(23)02729-X. doi: 10.1016/j.eururo.2023.
    >> Share

  231. REMMERS S, Bangma CH, Godtman RA, Carlsson SV, et al
    Relationship Between Baseline Prostate-specific Antigen on Cancer Detection and Prostate Cancer Death: Long-term Follow-up from the European Randomized Study of Screening for Prostate Cancer.
    Eur Urol. 2023 Apr 21:S0302-2838(23)02709-4. doi: 10.1016/j.eururo.2023.
    >> Share

  232. BEIJE N, Abida W, Antonarakis ES, Castro E, et al
    PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues.
    Eur Urol. 2023 Apr 20:S0302-2838(23)02716-1. doi: 10.1016/j.eururo.2023.
    >> Share

  233. LARA PN JR, Mayerson E, Gertz E, Tangen C, et al
    Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel.
    Eur Urol. 2023 Apr 19:S0302-2838(23)02715-X. doi: 10.1016/j.eururo.2023.
    >> Share

  234. HEMMINKI K, Ji J, Sundquist J
    Re: Mark N. Brook, Holly Ni Raghallaigh, Koveela Govindasami, et al. Family History of Prostate Cancer and Survival Outcomes in the UK Genetic Prostate Cancer Study. Eur Urol 2023;83:257-66.
    Eur Urol. 2023 Apr 13:S0302-2838(23)02718-5. doi: 10.1016/j.eururo.2023.
    >> Share

  235. BROOK MN, Ni Raghallaigh H, Kote-Jarai Z, Eeles RA, et al
    Reply to Kari Hemminki, Jianguang Ji, and Jan Sundquist's Letter to the Editor re: Mark N. Brook, Holly Ni Raghallaigh, Koveela Govindasami, et al. Family History of Prostate Cancer and Survival Outcomes in the UK Genetic Prostate Cancer Study. Eur Ur
    Eur Urol. 2023 Apr 13:S0302-2838(23)02719-7. doi: 10.1016/j.eururo.2023.
    >> Share

  236. CHOW KM, So WZ, Lee HJ, Lee A, et al
    Head-to-head Comparison of the Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography and Conventional Imaging Modalities for Initial Staging of Intermediate- to High-risk Prostate Cancer: A Systematic Review and Meta-a
    Eur Urol. 2023 Apr 7:S0302-2838(23)02640-4. doi: 10.1016/j.eururo.2023.
    >> Share

  237. ADELEKE S, Ghose A, Boussios S
    Re: Pain and Health-related Quality of Life with Olaparib Versus Physician's Choice of Next-generation Hormonal Drug in Patients with Metastatic Castration-resistant Prostate Cancer with Homologous Recombination Repair Gene Alterations (PROfound): An
    Eur Urol. 2023 Apr 7:S0302-2838(23)02702-1. doi: 10.1016/j.eururo.2023.
    >> Share

  238. MORRIS MJ, Sartor O, de Bono JS, Fizazi K, et al
    Reply to Timothee Olivier, Kerrington Powell, Vinay Prasad. Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.022.
    Eur Urol. 2023 Apr 7:S0302-2838(23)02706-9. doi: 10.1016/j.eururo.2023.
    >> Share

  239. MAYO ZS, Parker SM, Kilic SS, Weleff J, et al
    Disparities in Prostate Cancer Diagnoses Among Persons Experiencing Homelessness.
    Eur Urol. 2023 Apr 6:S0302-2838(23)02704-5. doi: 10.1016/j.eururo.2023.
    >> Share

  240. DE VOS II, Meertens A, Hogenhout R, Remmers S, et al
    A Detailed Evaluation of the Effect of Prostate-specific Antigen-based Screening on Morbidity and Mortality of Prostate Cancer: 21-year Follow-up Results of the Rotterdam Section of the European Randomised Study of Screening for Prostate Cancer.
    Eur Urol. 2023 Apr 5:S0302-2838(23)02669-6. doi: 10.1016/j.eururo.2023.
    >> Share

  241. NIK-AHD F, Cooperberg MR, Freedland SJ
    Reply to Sandra Patricia Garcia Nader, Sebastian Pena Rodriguez, and Cesar Alejandro Diaz Ritter's Letter to the Editor re: Farnoosh Nik-Ahd, Andrew Jarjour, Jane Figueiredo, et al. Prostate-specific Antigen Screening in Transgender Patients. Eur Urol
    Eur Urol. 2023;83:e104.
    >> Share

  242. GARCIA NADER S, Pena Rodriguez S, Diaz Ritter CA
    Re: Farnoosh Nik-Ahd, Andrew Jarjour, Jane Figueiredo, et al. Prostate-specific Antigen Screening in Transgender Patients. Eur Urol. 2023;83:48-54.
    Eur Urol. 2023;83:e103.
    >> Share

  243. NETTO GJ, Amin MB, Comperat EM, Gill AJ, et al
    Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification.
    Eur Urol. 2023;83:301-303.
    >> Share

  244. VINCE RA JR, Sun Y, Mahal B, Ginsburg K, et al
    The Impact of a Statewide Active Surveillance Initiative: A Roadmap for Increasing Active Surveillance Utilization Nationwide.
    Eur Urol. 2023;83:307-310.
    >> Share

  245. CHENG Q, Butler W, Zhou Y, Zhang H, et al
    Erratum to "Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy" [Eur Urol 2022;81(5):446-55].
    Eur Urol. 2023 Apr 1:S0302-2838(23)02697-0. doi: 10.1016/j.eururo.2023.
    >> Share

    March 2023
  246. GUO C, Figueiredo I, Gurel B, Neeb A, et al
    Erratum to "B7-H3 as a Therapeutic Target in Advanced Prostate Cancer" [Eur Urol 2023;83(3):224-38].
    Eur Urol. 2023 Mar 22:S0302-2838(23)02645-3. doi: 10.1016/j.eururo.2023.
    >> Share

  247. SEIFERT R, Emmett L, Rowe SP, Herrmann K, et al
    Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2).
    Eur Urol. 2023 Mar 17:S0302-2838(23)02574-5. doi: 10.1016/j.eururo.2023.
    >> Share

  248. KENIGSBERG AP, Ahdoot M, Turkbey B, Pinto PA, et al
    Re: Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only.
    Eur Urol. 2023 Mar 10:S0302-2838(23)02631-3. doi: 10.1016/j.eururo.2023.
    >> Share

  249. POSTEMA AW, Jager A, Mischi M, Salomon G, et al
    Re: Multiparametric Ultrasound Versus Multiparametric MRI to Diagnose Prostate Cancer (CADMUS): A Prospective, Multicentre, Paired-cohort, Confirmatory Study.
    Eur Urol. 2023 Mar 8:S0302-2838(23)02635-0. doi: 10.1016/j.eururo.2023.
    >> Share

  250. ROY S, Sun Y, Morgan SC, Wallis CJD, et al
    Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis Targeted Therapy in Metastatic Castrate-resistant Prostate Cancer: A Secondary Analysis of the COU-AA-302 Trial.
    Eur Urol. 2023 Mar 7:S0302-2838(23)02626-X. doi: 10.1016/j.eururo.2023.
    >> Share

  251. HABUCHI T
    Re: Continuous Enzalutamide After Progression of Metastatic Castration-resistant Prostate Cancer Treated with Docetaxel (PRESIDE): An International, Randomised, Phase 3b Study.
    Eur Urol. 2023 Mar 2:S0302-2838(23)02630-1. doi: 10.1016/j.eururo.2023.
    >> Share

  252. SHEE K, Cowan JE, Balakrishnan A, Escobar D, et al
    Limited Relevance of the Very Low Risk Prostate Cancer Classification in the Modern Era: Results from a Large Institutional Active Surveillance Cohort.
    Eur Urol. 2023 Mar 2:S0302-2838(23)02622-2. doi: 10.1016/j.eururo.2023.
    >> Share

  253. FLETCHER P, De Santis M, Ippoliti S, Orecchia L, et al
    Vector Prostate Biopsy: A Novel Magnetic Resonance Imaging/Ultrasound Image Fusion Transperineal Biopsy Technique Using Electromagnetic Needle Tracking Under Local Anaesthesia.
    Eur Urol. 2023;83:249-256.
    >> Share

  254. CIMADAMORE A, Lopez-Beltran A, Cheng L, Montironi R, et al
    Re: George J. Netto, Mahul B. Amin, Eva M. Comperat, et al. Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.0
    Eur Urol. 2023;83:e84-e86.
    >> Share

    February 2023
  255. CHEN F, Madduri RK, Rodriguez AA, Darst BF, et al
    Evidence of Novel Susceptibility Variants for Prostate Cancer and a Multiancestry Polygenic Risk Score Associated with Aggressive Disease in Men of African Ancestry.
    Eur Urol. 2023 Feb 27:S0302-2838(23)02561-7. doi: 10.1016/j.eururo.2023.
    >> Share

  256. ILIE G, Rendon R, Mason R, MacDonald C, et al
    A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial.
    Eur Urol. 2023 Feb 21:S0302-2838(23)02581-2. doi: 10.1016/j.eururo.2023.
    >> Share

  257. PONTES-SILVA A
    Re: Sophie Knipper, Mehrdad Mehdi Irai, Ricarda Simon, et al. Cohort Study of Oligorecurrent Prostate Cancer Patients: Oncological Outcomes of Patients Treated with Salvage Lymph Node Dissection via Prostate-specific Membrane Antigen-radioguided Surge
    Eur Urol. 2023 Feb 14:S0302-2838(23)02583-6. doi: 10.1016/j.eururo.2023.
    >> Share

  258. BERNARDINO R, Fleshner N
    Re: Sensitivity of Multiparametric MRI and Targeted Biopsy for Detection of Adverse Pathologies (Cribriform Gleason Pattern 4 and Intraductal Carcinoma): Correlation of Detected and Missed Prostate Cancer Foci with Whole Mount Histopathology.
    Eur Urol. 2023 Feb 13:S0302-2838(23)02573-3. doi: 10.1016/j.eururo.2023.
    >> Share

  259. SCHILHAM MGM, Rijpkema M, Scheenen T, Hermsen R, et al
    Reply to Francesco Montorsi, Simone Scuderi, Alberto Briganti, and Giorgio Gandaglia's Letter to the Editor re: Melline G.M. Schilham, Mark Rijpkema, Tom Scheenen, et al. How Advanced Imaging Will Guide Therapeutic Strategies for Patients with Newly D
    Eur Urol. 2023 Feb 11:S0302-2838(23)02564-2. doi: 10.1016/j.eururo.2023.
    >> Share

  260. OLIVIER T, Tsantoulis P, Prasad V
    Re: Darolutamide and Survival in Metastatic, Hormone-sensitive Prostate Cancer.
    Eur Urol. 2023 Feb 11:S0302-2838(23)02567-8. doi: 10.1016/j.eururo.2023.
    >> Share

  261. MONTORSI F, Scuderi S, Briganti A, Gandaglia G, et al
    Re: Melline G.M. Schilham, Mark Rijpkema, Tom Scheenen, et al. How Advanced Imaging Will Guide Therapeutic Strategies for Patients with Newly Diagnosed Prostate Cancer in the Years to Come. Eur Urol 2022;82:578-80.
    Eur Urol. 2023 Feb 9:S0302-2838(23)02563-0. doi: 10.1016/j.eururo.2022.
    >> Share

  262. KIM KM, Kim JH, Chung BI
    Re: Sigrid V. Carlsson, Rebecka Arnsrud Godtman, Carl-Gustav Pihl, et al. Young Age on Starting Prostate-specific Antigen Testing Is Associated with a Greater Reduction in Prostate Cancer Mortality: 24-Year Follow-up of the Goteborg Randomized Populat
    Eur Urol. 2023 Feb 9:S0302-2838(23)02562-9. doi: 10.1016/j.eururo.2022.
    >> Share

  263. VARATHARAJAN A, Olivier T, Prasad V
    Prostate-specific Membrane Antigen Positron Emission Tomography in the Staging of Newly Diagnosed Prostate Cancer: Is More Sensitivity Always Better?
    Eur Urol. 2023 Feb 9:S0302-2838(23)02565-4. doi: 10.1016/j.eururo.2023.
    >> Share

  264. FORTUIN A, van Asten J, Veltien A, Philips B, et al
    Small Suspicious Lymph Nodes Detected on Ultrahigh-field Magnetic Resonance Imaging (MRI) in Patients with Prostate Cancer with High Risk of Nodal Metastases: The First In-patient Study on Ultrasmall Superparamagnetic Iron Oxide-enhanced 7T MRI.
    Eur Urol. 2023 Feb 2:S0302-2838(23)00003-9. doi: 10.1016/j.eururo.2023.
    >> Share

  265. BORGHESI M, Bauckneht M, Terrone C
    Re: Radical Prostatectomy Without Prior Biopsy Following Multiparametric Magnetic Resonance Imaging and Prostate-specific Membrane Antigen Positron Emission Tomography.
    Eur Urol. 2023;83:185-186.
    >> Share

  266. POWELL K, Burns MC, Prasad V
    Relugolix: Five Reasons Why the US Food and Drug Administration Should Have Exercised Restraint.
    Eur Urol. 2023;83:101-102.
    >> Share

  267. STUDENT V JR, Tudos Z, Studentova Z, Cesak O, et al
    Effect of Peritoneal Fixation (PerFix) on Lymphocele Formation in Robot-assisted Radical Prostatectomy with Pelvic Lymphadenectomy: Results of a Randomized Prospective Trial.
    Eur Urol. 2023;83:154-162.
    >> Share

    January 2023
  268. BROOKMAN-MAY SD, May M
    Re: Prostate Cancer Polygenic Risk Score and Prediction of Lethal Prostate Cancer.
    Eur Urol. 2023 Jan 27:S0302-2838(23)00013-1. doi: 10.1016/j.eururo.2023.
    >> Share

  269. MELL LK, Pugh SL, Jones CU, Nelson TJ, et al
    Effects of Androgen Deprivation Therapy on Prostate Cancer Outcomes According to Competing Event Risk: Secondary Analysis of a Phase 3 Randomised Trial.
    Eur Urol. 2023 Jan 27:S0302-2838(23)00056-8. doi: 10.1016/j.eururo.2023.
    >> Share

  270. COMPERAT E, Oszwald A, Wasinger G
    Re: Percentage Gleason Pattern 4 and PI-RADS Score Predict Upgrading in Biopsy Grade Group 2 Prostate Cancer Patients Without Cribriform Pattern.
    Eur Urol. 2023 Jan 25:S0302-2838(23)00015-5. doi: 10.1016/j.eururo.2023.
    >> Share

  271. SHAH TT, Kanthabalan A, Otieno M, Pavlou M, et al
    Corrigendum to "Magnetic Resonance Imaging and targeted biopsies compared to transperineal mapping biopsies prior to salvage focal therapy/ablation in localised and metastatic recurrent prostate cancer after radiotherapy. Primary Outcomes from the FOR
    Eur Urol. 2023 Jan 19:S0302-2838(23)00004-0. doi: 10.1016/j.eururo.2023.
    >> Share

  272. SIRUFO MM, Ginaldi L, De Martinis M
    Re: Yaw A. Nyame, Matthew R. Cooperberg, Marcus G. Cumberbatch, et al. Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care. Eur Urol 2022;82:341-51.
    Eur Urol. 2023 Jan 18:S0302-2838(22)02920-7. doi: 10.1016/j.eururo.2022.
    >> Share

  273. MACLENNAN S, Azevedo N, Duncan E, Dunsmore J, et al
    Mapping European Association of Urology Guideline Practice Across Europe: An Audit of Androgen Deprivation Therapy Use Before Prostate Cancer Surgery in 6598 Cases in 187 Hospitals Across 31 European Countries.
    Eur Urol. 2023 Jan 11:S0302-2838(22)02919-0. doi: 10.1016/j.eururo.2022.
    >> Share

  274. ALBERS P
    Re: Association of Prostate-specific Antigen Screening Rates with Subsequent Metastatic Prostate Cancer Incidence at US Veterans Health Administration Facilities: Prostate cancer screening needs not only to be well meant but also well done.
    Eur Urol. 2023 Jan 9:S0302-2838(22)02852-4. doi: 10.1016/j.eururo.2022.
    >> Share

  275. LOEHR A, Chowdhury S, Abida W
    Reply to Feng Qi, Zicheng Xu, and Qing Zou's Letter to the Editor re: Andrea Loehr, Arif Hussain, Akash Patnaik, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucapar
    Eur Urol. 2023 Jan 7:S0302-2838(22)02872-X. doi: 10.1016/j.eururo.2022.
    >> Share

  276. BRATT O, Auvinen A
    Re: Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only.
    Eur Urol. 2023 Jan 7:S0302-2838(22)02915-3. doi: 10.1016/j.eururo.2022.
    >> Share

  277. CHANDRAN K, Grochot R, de Los Dolores Fenor De La Maza M, Yuan W, et al
    A Transgender Patient with Prostate Cancer: Lessons Learnt.
    Eur Urol. 2023 Jan 4:S0302-2838(22)02912-8. doi: 10.1016/j.eururo.2022.
    >> Share

  278. LABBAN M, Trinh QD, D'Amico AV
    Re: Population-based Randomized Trial of Screening for Clinically Significant Prostate Cancer ProScreen: A Pilot Study.
    Eur Urol. 2023 Jan 4:S0302-2838(22)02916-5. doi: 10.1016/j.eururo.2022.
    >> Share

  279. SEIBERT TM, Garraway IP, Plym A, Mahal BA, et al
    Genetic Risk Prediction for Prostate Cancer: Implications for Early Detection and Prevention.
    Eur Urol. 2023 Jan 4:S0302-2838(22)02870-6. doi: 10.1016/j.eururo.2022.
    >> Share

  280. QI F, Xu Z, Zou Q
    Re: Andrea Loehr, Arif Hussain, Akash Patnaik, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.0
    Eur Urol. 2023 Jan 3:S0302-2838(22)02873-1. doi: 10.1016/j.eururo.2022.
    >> Share

  281. NIK-AHD F, Jarjour A, Figueiredo J, Anger JT, et al
    Prostate-Specific Antigen Screening in Transgender Patients.
    Eur Urol. 2023;83:48-54.
    >> Share

  282. CLARKE NW
    Following the Narrow Path.
    Eur Urol. 2023;83:27-28.
    >> Share

  283. WEI Y, Huang H, Ye L
    Re: George J. Netto, Mahul B. Amin, Daniel M. Berney, et al. The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs-Part B: Prostate and Urinary Tract Tumors. Eur Urol. 2022:82:469-82.
    Eur Urol. 2023;83:e15.
    >> Share

  284. RUBIN MA, Amin MB, Comperat E, Gill A, et al
    Reply to Yongbao Wei, Haijian Huang, and Liefu Ye's Letter to the Editor re: George J. Netto, Mahul B. Amin, Daniel M. Berney, et al. The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs-Part B: Pro
    Eur Urol. 2023;83:e16-e17.
    >> Share

    December 2022
  285. TURKERI L, Ozen H
    Re: The Natural History of Untreated Biopsy Grade Group Progression and Delayed Definitive Treatment for Men on Active Surveillance for Early-stage Prostate Cancer.
    Eur Urol. 2022 Dec 20:S0302-2838(22)02854-8. doi: 10.1016/j.eururo.2022.
    >> Share

  286. BANGMA CH
    Re: Modern Imaging in Prostate Cancer: Do We Treat Patients or Their Scans?
    Eur Urol. 2022 Dec 15:S0302-2838(22)02833-0. doi: 10.1016/j.eururo.2022.
    >> Share

  287. YU EY, Piulats JM, Gravis G, Fong PCC, et al
    Corrigendum to "Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study" [Eur Urol 83 (2023) 15-26].
    Eur Urol. 2022 Dec 15:S0302-2838(22)02844-5. doi: 10.1016/j.eururo.2022.
    >> Share

  288. BROOK MN, Ni Raghallaigh H, Govindasami K, Dadaev T, et al
    Family History of Prostate Cancer and Survival Outcomes in the UK Genetic Prostate Cancer Study.
    Eur Urol. 2022 Dec 15:S0302-2838(22)02838-X. doi: 10.1016/j.eururo.2022.
    >> Share

  289. PLATA BELLO A, Touijer K
    Re: Adjuvant Versus Early Salvage Radiation Therapy After Radical Prostatectomy for pN1 Prostate Cancer and the Risk of Death.
    Eur Urol. 2022 Dec 15:S0302-2838(22)02855-X. doi: 10.1016/j.eururo.2022.
    >> Share

  290. BOGEMANN M, Shore ND, Smith MR, Tammela TLJ, et al
    Erratum to "Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial" [Eur Urol 2022].
    Eur Urol. 2022 Dec 14:S0302-2838(22)02837-8. doi: 10.1016/j.eururo.2022.
    >> Share

  291. CARLSSON SV, Godtman RA, Pihl CG, Vickers A, et al
    Corrigendum to "Young Age on Starting Prostate-specific Antigen Testing Is Associated with a Greater Reduction in Prostate Cancer Mortality: 24-Year Follow-up of the Goteborg Randomized Population-based Prostate Cancer Screening Trial" [Eur Urol (2022
    Eur Urol. 2022 Dec 8:S0302-2838(22)02839-1. doi: 10.1016/j.eururo.2022.
    >> Share

  292. GILLESSEN S, Bossi A, Davis ID, de Bono J, et al
    Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.
    Eur Urol. 2022 Dec 6:S0302-2838(22)02789-0. doi: 10.1016/j.eururo.2022.
    >> Share

    November 2022
  293. VILLERS A, Olivier J
    Re: Oncologic Outcomes of Total Length Gleason Pattern 4 on Biopsy in Men with Grade Group 2 Prostate Cancer.
    Eur Urol. 2022 Nov 26:S0302-2838(22)02699-9. doi: 10.1016/j.eururo.2022.
    >> Share

  294. BUKAVINA L, Luckenbaugh AN, Hofman MS, Hope T, et al
    Incorporating Prostate-specific Membrane Antigen Positron Emission Tomography in Management Decisions for Men with Newly Diagnosed or Biochemically Recurrent Prostate Cancer.
    Eur Urol. 2022 Nov 17:S0302-2838(22)02780-4. doi: 10.1016/j.eururo.2022.
    >> Share

  295. ALBERTSEN PC
    Screening for Prostate Cancer with Prostate-specific Antigen: The Journey Continues.
    Eur Urol. 2022 Nov 10. pii: S0302-2838(22)02772.
    >> Share

  296. HU M, Ye L
    Re: Jihad H. Kaouk, Ethan L. Ferguson, Alp Tuna Beksac, et al. Single-port Robotic Transvesical Partial Prostatectomy for Localized Prostate Cancer: Initial Series and Description of Technique. Eur Urol. 2022;82:551-58.
    Eur Urol. 2022 Nov 7. pii: S0302-2838(22)02779.
    >> Share

  297. SHENDEROV E, Antonarakis ES
    B7-H3 and Prostate Cancer: New Therapeutic Dance Partners.
    Eur Urol. 2022 Nov 5. pii: S0302-2838(22)02773.
    >> Share

  298. YAO X, Duan C, Li B, Wu X, et al
    Re: Hilda A. de Barros, Matthias N. van Oosterom, Maarten L. Donswijk, et al. Robot-assisted Prostate-specific Membrane Antigen-radioguided Salvage Surgery in Recurrent Prostate Cancer Using a DROP-IN Gamma Probe: The First Prospective Feasibility Stu
    Eur Urol. 2022 Nov 2. pii: S0302-2838(22)02720.
    >> Share

  299. CARLSSON SV, Arnsrud Godtman R, Pihl CG, Vickers A, et al
    Young Age on Starting Prostate-specific Antigen Testing Is Associated with a Greater Reduction in Prostate Cancer Mortality: 24-Year Follow-up of the Goteborg Randomized Population-based Prostate Cancer Screening Trial.
    Eur Urol. 2022 Nov 2. pii: S0302-2838(22)02715.
    >> Share

  300. XU P, Chen C, Chen B, Bi E, et al
    Long-term Follow-up of Detaenial Sigmoid Neobladder Reconstruction for Paediatric Patients with Bladder and Prostate Rhabdomyosarcoma: Technique and Results from a Single High-volume Centre.
    Eur Urol. 2022;82:543-550.
    >> Share

  301. MARTINI A, Mottet N, Montorsi F, Necchi A, et al
    A Plea for Economically Sustainable Evidence-based Guidelines.
    Eur Urol. 2022;82:449-451.
    >> Share

    October 2022
  302. FERGUSON EL, Kaouk JH
    Reply to Minxiong Hu and Liefu Ye's Letter to the Editor re: Jihad H. Kaouk, Ethan L. Ferguson, Alp Tuna Beksac, et al. Single-port Robotic Transvesical Partial Prostatectomy for Localized Prostate Cancer: Initial Series and Description of Technique.
    Eur Urol. 2022 Oct 25. pii: S0302-2838(22)02722.
    >> Share

  303. AYATI N, Herrmann K, Fanti S, Murphy DG, et al
    More Accurate Imaging Is Not Stage Migration: Time To Move from "Hubble" to "Webb" in Hormone-sensitive Prostate Cancer.
    Eur Urol. 2022 Oct 21. pii: S0302-2838(22)02714.
    >> Share

  304. FERGUSON EL, Kaouk JH
    Reply to Shangqing Ren, Xu Hu, Kai Wang, Qian Lv, and Wang Dong's Letter to the Editor re: Jihad H. Kaouk, Ethan L. Ferguson, Alp Tuna Beksac, et al. Single-port Robotic Transvesical Partial Prostatectomy for Localized Prostate Cancer: Initial Series
    Eur Urol. 2022 Oct 21. pii: S0302-2838(22)02717.
    >> Share

  305. VANDEKERKHOVE G
    BRCA Reversion Mutations in Metastatic Castration-Resistant Prostate Cancer.
    Eur Urol. 2022 Oct 20. pii: S0302-2838(22)02708.
    >> Share

  306. REN S, Hu X, Wang K, Lv Q, et al
    Re: Jihad H. Kaouk, Ethan L. Ferguson, Alp Tuna Beksac, et al. Single-port Robotic Transvesical Partial Prostatectomy for Localized Prostate Cancer: Initial Series and Description of Technique. Eur Urol. 2022;82:551-58.
    Eur Urol. 2022 Oct 19. pii: S0302-2838(22)02716.
    >> Share

  307. DE BARROS HA, van Oosterom MN, Donswijk ML, Hendrikx JJMA, et al
    Reply to Xiangyang Yao, Chen Duan, Bo Li, Xiaoliang Wu and Hua Xu's Letter to the Editor Re: Hilda A. de Barros, Matthias N. van Oosterom, Maarten L. Donswijk, et al. Robot-assisted Prostate-specific Membrane Antigen-radioguided Salvage Surgery in Rec
    Eur Urol. 2022 Oct 19. pii: S0302-2838(22)02718.
    >> Share

  308. LOEHR A, Hussain A, Patnaik A, Bryce AH, et al
    Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib.
    Eur Urol. 2022 Oct 12. pii: S0302-2838(22)02639.
    >> Share

  309. WANG B, Li C, Zheng X, Yao K, et al
    Re: Giorgio Gandaglia, Elio Mazzone, Armando Stabile, et al. Prostate-specific Membrane Antigen Radioguided Surgery to Detect Nodal Metastases in Primary Prostate Cancer Patients Undergoing Robot-assisted Radical Prostatectomy and Extended Pelvic Lymp
    Eur Urol. 2022 Oct 6. pii: S0302-2838(22)02696.
    >> Share

  310. JACOBS MF, Greenberg SE
    Prostate Cancer Genomic Testing: When Sequencing Is Not Sufficient and Germline Testing Is Necessary.
    Eur Urol. 2022 Oct 5. pii: S0302-2838(22)02690.
    >> Share

  311. MAXWELL KN, Pritchard CC
    Reply to Hela Sassi, Olivier Caron, and Etienne Rouleau's Letter to the Editor re: Kara N. Maxwell, Heather H. Cheng, Jacquelyn Powers, et al. Inherited TP53 Variants and Risk of Prostate Cancer. Eur Urol 2022;81:243-50.
    Eur Urol. 2022 Oct 3. pii: S0302-2838(22)02698.
    >> Share

    September 2022
  312. HALL WA, Shoag J, Spratt DE
    Re: MRI-guided Focused Ultrasound Focal Therapy for Patients with Intermediate-risk Prostate Cancer: A Phase 2b, Multicentre Study.
    Eur Urol. 2022 Sep 29. pii: S0302-2838(22)02618.
    >> Share

  313. DEVOS G, Tosco L, Baldewijns M, Gevaert T, et al
    ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer.
    Eur Urol. 2022 Sep 24. pii: S0302-2838(22)02638.
    >> Share

  314. SCHILHAM MGM, Rijpkema M, Scheenen T, Hermsen R, et al
    How Advanced Imaging Will Guide Therapeutic Strategies for Patients with Newly Diagnosed Prostate Cancer in the Years to Come.
    Eur Urol. 2022 Sep 24. pii: S0302-2838(22)02634.
    >> Share

  315. SASSI H, Caron O, Rouleau E
    Re: Kara N. Maxwell, Heather H. Cheng, Jacquelyn Powers, et al. Inherited TP53 Variants and Risk of Prostate Cancer. Eur Urol 2022;81:243-50: Off-core Li-Fraumeni Syndrome Spectrum Cancers: Increasing Interest for Prostate Cancer?
    Eur Urol. 2022 Sep 21. pii: S0302-2838(22)02632.
    >> Share

  316. BARNETT ES, Schultz N, Stopsack KH, Lam ET, et al
    Analysis of BRCA2 Copy Number Loss and Genomic Instability in Circulating Tumor Cells from Patients with Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2022 Sep 16. pii: S0302-2838(22)02561.
    >> Share

  317. ZAPATERO A, Calvo FA, Gonzalez San-Segundo C, Alvarez A, et al
    Reply to Leonard P. Bokhorst and Berdine L. Heesterman's Words of Wisdom re: High-dose Radiotherapy and Risk-adapted Androgen Deprivation in Localised Prostate Cancer (DART 01/05): 10-Year Results of a Phase 3 Randomised, Controlled Trial. Eur Urol. 2
    Eur Urol. 2022 Sep 14. pii: S0302-2838(22)02624.
    >> Share

  318. TRUONG H, Breen K, Nandakumar S, Sjoberg DD, et al
    Gene-based Confirmatory Germline Testing Following Tumor-only Sequencing of Prostate Cancer.
    Eur Urol. 2022 Sep 14. pii: S0302-2838(22)02619.
    >> Share

  319. GUO C, Figueiredo I, Gurel B, Neeb A, et al
    B7-H3 as a Therapeutic Target in Advanced Prostate Cancer.
    Eur Urol. 2022 Sep 13. pii: S0302-2838(22)02633.
    >> Share

  320. DZIMITROWICZ HE, Armstrong AJ
    Triplet Therapy: Entering the Metaverse of Metastatic Hormone-sensitive Prostate Cancer Treatment.
    Eur Urol. 2022 Sep 13. pii: S0302-2838(22)02621.
    >> Share

  321. LEE DJ, Hausler R, Maxwell KN
    Reply to Joanne L. Dickinson, Georgea R. Foley, and Liesel M. FitzGerald's Letter to the Editor re: Daniel J. Lee, Ryan Hausler, Anh N. Le, et al. Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer. Eur Urol 2022;81:
    Eur Urol. 2022 Sep 13. pii: S0302-2838(22)02616.
    >> Share

  322. OLIVIER T, Powell K, Prasad V
    Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial.
    Eur Urol. 2022 Sep 9. pii: S0302-2838(22)02613.
    >> Share

  323. BOGEMANN M, Shore ND, Smith MR, Tammela TLJ, et al
    Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial.
    Eur Urol. 2022 Sep 8. pii: S0302-2838(22)02532.
    >> Share

  324. LI H, Zhang Y, Xu H
    Reply to Adam G. Sowalsky, Stephen R. Plymate, Michael C. Haffner, Johann S. de Bono, and Adam Sharp's Letter to the Editor re: Heng Li, Yucong Zhang, Dong Li, et al. Androgen Receptor Splice Variant 7 Predicts Shorter Response in Patients with Metast
    Eur Urol. 2022 Sep 7. pii: S0302-2838(22)02565.
    >> Share

  325. DICKINSON JL, Foley GR, FitzGerald LM
    Re: Daniel J. Lee, Ryan Hausler, Anh N. Le, et al. Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer. Eur Urol 2022;81:559-67.
    Eur Urol. 2022 Sep 5. pii: S0302-2838(22)02617.
    >> Share

  326. MONTORSI F, Bravi CA, Gandaglia G, Mottrie A, et al
    Re: Sophie Knipper, Mehrdad Mehdi Irai, Ricarda Simon, et al. Cohort Study of Oligorecurrent Prostate Cancer Patients: Oncological Outcomes of Patients Treated with Salvage Lymph Node Dissection via Prostate-specific Membrane Antigen-radioguided Surge
    Eur Urol. 2022 Sep 2. pii: S0302-2838(22)02612.
    >> Share

  327. BRISBANE WG, Priester AM, Ballon J, Kwan L, et al
    Targeted Prostate Biopsy: Umbra, Penumbra, and Value of Perilesional Sampling.
    Eur Urol. 2022;82:303-310.
    >> Share

    August 2022
  328. YU EY, Piulats JM, Gravis G, Fong PCC, et al
    Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study.
    Eur Urol. 2022 Aug 30. pii: S0302-2838(22)02554.
    >> Share

  329. SOWALSKY AG, Plymate SR, Haffner MC, de Bono JS, et al
    Re: Heng Li, Yucong Zhang, Dong Li, et al. Androgen Receptor Splice Variant 7 Predicts Shorter Response in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Deprivation Therapy. Eur Urol 2021;79:879-86 AR-V7 is Rare in Horm
    Eur Urol. 2022 Aug 26. pii: S0302-2838(22)02563.
    >> Share

  330. YANAGISAWA T, Rajwa P, Thibault C, Gandaglia G, et al
    Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis.
    Eur Urol. 2022 Aug 19. pii: S0302-2838(22)02551.
    >> Share

  331. CHANG D, Blanchard P, Siva S
    The Deep Blue of Prostate Cancer Metastasis Evolution: The LEVIATHAN Pooled Analysis.
    Eur Urol. 2022 Aug 19. pii: S0302-2838(22)02555.
    >> Share

  332. MONTORSI F, Gandaglia G, Robesti D, Deho F, et al
    Re: Kathia De Man, Nick Van Laeken, Vanessa Schelfhout, et al. (18)F-PSMA-11 Versus (68)Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Staging and Biochemical Recurrence of Prostate Cancer: A Prospective Double-blind Randomised Cross-
    Eur Urol. 2022 Aug 18. pii: S0302-2838(22)02557.
    >> Share

  333. GRIVAS N, Lardas M, Espinos EL, Lam TB, et al
    Prostate Cancer Detection Percentages of Repeat Biopsy in Patients with Positive Multiparametric Magnetic Resonance Imaging (Prostate Imaging Reporting and Data System/Likert 3-5) and Negative Initial Biopsy. A Mini Systematic Review.
    Eur Urol. 2022 Aug 16. pii: S0302-2838(22)02540.
    >> Share

  334. KAOUK JH, Ferguson EL, Beksac AT, Zeinab MA, et al
    Single-port Robotic Transvesical Partial Prostatectomy for Localized Prostate Cancer: Initial Series and Description of Technique.
    Eur Urol. 2022 Aug 12. pii: S0302-2838(22)02531.
    >> Share

  335. PETERS M, Eldred-Evans D, Kurver P, Falagario UG, et al
    Predicting the Need for Biopsy to Detect Clinically Significant Prostate Cancer in Patients with a Magnetic Resonance Imaging-detected Prostate Imaging Reporting and Data System/Likert >/=3 Lesion: Development and Multinational External Validation of
    Eur Urol. 2022 Aug 10. pii: S0302-2838(22)02537.
    >> Share

  336. DASGUPTA P
    Re: Artificial Intelligence for Diagnosis and Gleason Grading of Prostate Cancer: The PANDA Challenge.
    Eur Urol. 2022 Aug 9. pii: S0302-2838(22)02543.
    >> Share

  337. KESCH C, Hadaschik BA
    Re: Active Surveillance Plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial.
    Eur Urol. 2022 Aug 9. pii: S0302-2838(22)02546.
    >> Share

  338. DORFF TB, Morgans AK
    A Path to Precision Medicine in Prostate Cancer: Learning from "Negative" Trials of Targeted Therapies.
    Eur Urol. 2022 Aug 6. pii: S0302-2838(22)02527.
    >> Share

  339. CARVALHO FLF, Mossanen M, Van Allen EM, Mouw KW, et al
    Reply to Yuxuan Song, Yiqing Du, and Tao Xu's Letter to the Editor re: Matthew Mossanen, Filipe L.F. Carvalho, Vinayak Muralidhar, et al. Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy. Eur Urol 2022;81:466-73.
    Eur Urol. 2022 Aug 6. pii: S0302-2838(22)02534.
    >> Share

  340. SONG Y, Du Y, Xu T
    Re: Matthew Mossanena, Filipe L.F. Carvalhoa, Vinayak Muralidhar, et al. Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy. Eur Urol 2022;81:466-73.
    Eur Urol. 2022 Aug 5. pii: S0302-2838(22)02530.
    >> Share

  341. MA TM, Chu FI, Sandler H, Feng FY, et al
    Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN).
    Eur Urol. 2022 Aug 4. pii: S0302-2838(22)02523.
    >> Share

  342. WASHINGTON SL
    We Must Change Our Approach to Racial Disparities in Prostate Cancer.
    Eur Urol. 2022 Aug 4. pii: S0302-2838(22)02529.
    >> Share

  343. MEISSNER VH, Rauscher I, Schwamborn K, Neumann J, et al
    Radical Prostatectomy Without Prior Biopsy Following Multiparametric Magnetic Resonance Imaging and Prostate-specific Membrane Antigen Positron Emission Tomography.
    Eur Urol. 2022;82:156-160.
    >> Share

    July 2022
  344. BOSAS P, Zaleskis G, Characiejus D
    Re: Sylvia H.J. Jochems, Josef Fritz, Christel Haggstrom, Bengt Jarvholm, Par Stattin, Tanja Stocks. Smoking and Risk of Prostate Cancer and Prostate Cancer Death: A Pooled Study. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.03.033.
    Eur Urol. 2022 Jul 27. pii: S0302-2838(22)02478.
    >> Share

  345. VILASECA A, Ribal MJ
    Re: Darolutamide and Survival in Metastatic, Hormone-sensitive Prostate Cancer.
    Eur Urol. 2022 Jul 27. pii: S0302-2838(22)02526.
    >> Share

  346. JOCHEMS SHJ, Stattin P, Stocks T
    Reply to Paulius Bosas, Gintaras Zaleskis, and Dainius Characiejus's Letter to the Editor re: Sylvia H.J. Jochems, Josef Fritz, Christel Haggstrom, Bengt Jarvholm, Par Stattin, Tanja Stocks. Smoking and Risk of Prostate Cancer and Prostate Cancer Deat
    Eur Urol. 2022 Jul 27. pii: S0302-2838(22)02481.
    >> Share

  347. MURTHY V, Chilukuri S, Maitre P
    Re: Pawel Rajwa, Benjamin Pradere, Giorgio Gandaglia, et al. Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2022;82:82-96.
    Eur Urol. 2022 Jul 27. pii: S0302-2838(22)02480.
    >> Share

  348. LEVERIDGE M, Siemens DR
    Re: Effects of Magnetic Resonance Imaging Targeting on Overdiagnosis and Overtreatment of Prostate Cancer.
    Eur Urol. 2022 Jul 27. pii: S0302-2838(22)02528.
    >> Share

  349. BOKHORST LP, Heesterman BL
    Re: High-dose Radiotherapy and Risk-adapted Androgen Deprivation in Localised Prostate Cancer (DART 01/05): 10-Year Results of a Phase 3 Randomised, Controlled Trial.
    Eur Urol. 2022 Jul 25. pii: S0302-2838(22)02482.
    >> Share

  350. GANDAGLIA G, Mazzone E, Stabile A, Pellegrino A, et al
    Prostate-specific membrane antigen Radioguided Surgery to Detect Nodal Metastases in Primary Prostate Cancer Patients Undergoing Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: Results of a Planned Interim Analysis of a
    Eur Urol. 2022 Jul 22. pii: S0302-2838(22)02417.
    >> Share

  351. SAMARATUNGA H, Delahunt B, Egevad L
    Re: Valentin H. Meissner, Isabel Rauscher, Kristina Schwamborn, et al. Radical Prostatectomy Without Prior Biopsy Following Multiparametric Magnetic Resonance Imaging and Prostate-specific Membrane Antigen Positron Emission Tomography. Eur Urol. In pr
    Eur Urol. 2022;82:e15-e16.
    >> Share

  352. PADHANI AR, Schoots IG, Giannarini G
    Re: Targeted Prostate Biopsy: Umbra, Penumbra, and Value of Perilesional Sampling.
    Eur Urol. 2022;82:143-144.
    >> Share

  353. LENFANT L, Barret E, Roupret M, Rozet F, et al
    Transperineal Prostate Biopsy Is the New Black: What Are the Next Targets?
    Eur Urol. 2022;82:3-5.
    >> Share

  354. VAN LEEUWEN PJ, Emmett L
    (18)F-PSMA-11 as an Attractive (68)Ga-PSMA-11 Alternative for Prostate Cancer Imaging.
    Eur Urol. 2022 Jul 1. pii: S0302-2838(22)02416.
    >> Share

    June 2022
  355. MARRA G, Agnello M, Giordano A, Soria F, et al
    Robotic Radical Prostatectomy for Prostate Cancer in Renal Transplant Recipients: Results from a Multicenter Series.
    Eur Urol. 2022 Jun 21. pii: S0302-2838(22)02400.
    >> Share

  356. SAAD F, de Bono J, Barthelemy P, Dorff T, et al
    Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1.
    Eur Urol. 2022 Jun 21. pii: S0302-2838(22)02407.
    >> Share

  357. KNIPPER S, Mehdi Irai M, Simon R, Koehler D, et al
    Cohort Study of Oligorecurrent Prostate Cancer Patients: Oncological Outcomes of Patients Treated with Salvage Lymph Node Dissection via Prostate-specific Membrane Antigen-radioguided Surgery.
    Eur Urol. 2022 Jun 16. pii: S0302-2838(22)02408.
    >> Share

  358. VICKERS AJ
    Corrigendum to "Effects of Magnetic Resonance Imaging Targeting on Overdiagnosis and Overtreatment of Prostate Cancer" [Eur Urol 2021;80:567-72].
    Eur Urol. 2022 Jun 14. pii: S0302-2838(22)02398.
    >> Share

  359. DE MAN K, Van Laeken N, Schelfhout V, Fendler WP, et al
    (18)F-PSMA-11 Versus (68)Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Staging and Biochemical Recurrence of Prostate Cancer: A Prospective Double-blind Randomised Cross-over Trial.
    Eur Urol. 2022 Jun 8. pii: S0302-2838(22)02383.
    >> Share

  360. REDDY D, Ahmed HU
    Reply to Francesco Montorsi, Armando Stabile, Elio Mazzone, Giorgio Gandaglia, and Alberto Briganti's Letter to the Editor re: Deepika Reddy, Max Peters, Taimur T. Shah, et al. Cancer Control Outcomes Following Focal Therapy Using High-intensity Focus
    Eur Urol. 2022 Jun 8. pii: S0302-2838(22)02412.
    >> Share

  361. KISHAN AU, Spratt DE
    Reply to Yongfeng Lao, Yanan Wang, and Zhilong Dong's Letter to the Editor re: Amar U. Kishan, Xiaoyan Wang, Yilun Sun, et al. High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An
    Eur Urol. 2022 Jun 7. pii: S0302-2838(22)02410.
    >> Share

  362. BEYER K, MacLennan S, Van Hemelrijck M
    Reply to Ruobing Lei, Yuehuan Li, and Yaolong Chen's Letter to the Editor re: Katharina Beyer, Lisa Moris, Michael Lardas, et al. Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resi
    Eur Urol. 2022 Jun 7. pii: S0302-2838(22)02388.
    >> Share

  363. CRABB SJ, Griffiths G, Dunkley D, Downs N, et al
    Overall Survival Update for Patients with Metastatic Castration-resistant Prostate Cancer Treated with Capivasertib and Docetaxel in the Phase 2 ProCAID Clinical Trial.
    Eur Urol. 2022 Jun 7. pii: S0302-2838(22)02393.
    >> Share

  364. LAO Y, Wang Y, Dong Z
    Re: Amar U. Kishan, Xiaoyan Wang, Yilun Sun, et al. High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium.
    Eur Urol. 2022 Jun 7. pii: S0302-2838(22)02411.
    >> Share

  365. ROCCO B, Sighinolfi MC, Coelho RF, Covas Moschovas M, et al
    Re: Trends in Incidence of Metastatic Prostate Cancer in the US.
    Eur Urol. 2022 Jun 2. pii: S0302-2838(22)02271.
    >> Share

  366. MONTORSI F, Stabile A, Mazzone E, Gandaglia G, et al
    Re: Deepika Reddy, Max Peters, Taimur T. Shah, et al. Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience. Eur Urol 2022;81:407-13
    Eur Urol. 2022 Jun 2. pii: S0302-2838(22)02394.
    >> Share

    May 2022
  367. BURNS D, Anokian E, Saunders EJ, Bristow RG, et al
    Rare Germline Variants Are Associated with Rapid Biochemical Recurrence After Radical Prostate Cancer Treatment: A Pan Prostate Cancer Group Study.
    Eur Urol. 2022 May 31. pii: S0302-2838(22)02341.
    >> Share

  368. PLYM A, Zhang Y, Stopsack KH, Delcoigne B, et al
    A Healthy Lifestyle in Men at Increased Genetic Risk for Prostate Cancer.
    Eur Urol. 2022 May 27. pii: S0302-2838(22)02342.
    >> Share

  369. LEI R, Li Y, Chen Y
    Re: Katharina Beyer, Lisa Moris, Michael Lardas, et al. Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resistant Prostate Cancer: An Update from the PIONEER Consortium. Eur Urol 202
    Eur Urol. 2022 May 26. pii: S0302-2838(22)02387.
    >> Share

  370. WEI Y, Ye D, Zhu Y
    Re: Yaw A. Nyame, Matthew R. Cooperberg, Marcus G. Cumberbatch, et al. Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.03.007.
    Eur Urol. 2022 May 19. pii: S0302-2838(22)02339.
    >> Share

  371. SONG Y, Du Y, Xu T
    Re: Jiatong Zhou, Jie Ding, Jun Qi. Comparison of Typical Prostate Adenocarcinoma and Rare Histological Variant Prostate Cancer Showed Different Characteristics and Prognosis: A Surveillance, Epidemiology, and End Results Database Analysis. Eur Urol.
    Eur Urol. 2022 May 19. pii: S0302-2838(22)02334.
    >> Share

  372. BERLIN A, Brierley J, Cornford P, Chung P, et al
    TNM Staging of Prostate Cancer: Challenges in Securing a Globally Applicable Classification.
    Eur Urol. 2022 May 10. pii: S0302-2838(22)02267.
    >> Share

  373. RAKAUSKAS A, Valerio M, Roth B
    Re: Multiparametric Ultrasound Versus Multiparametric MRI To Diagnose Prostate Cancer (CADMUS): A Prospective, Multicentre, Paired-cohort, Confirmatory Study.
    Eur Urol. 2022 May 4. pii: S0302-2838(22)01815.
    >> Share

  374. JOCHEMS SHJ, Fritz J, Haggstrom C, Jarvholm B, et al
    Smoking and Risk of Prostate Cancer and Prostate Cancer Death: A Pooled Study.
    Eur Urol. 2022 May 3. pii: S0302-2838(22)01804.
    >> Share

  375. MARRA G, Stabile A, Gontero P, Montorsi F, et al
    Re: Valentin H. Meissner, Isabel Rauscher, Kristina Schwamborn, et al. Radical Prostatectomy Without Prior Biopsy Following Multiparametric Magnetic Resonance Imaging and Prostate-specific Membrane Antigen Positron Emission Tomography. Eur Urol. In pr
    Eur Urol. 2022;81:e115-e116.
    >> Share

  376. LEI Y, Han S, Xing N
    Re: Valentin H. Meissner, Isabel Rauscher, Kristina Schwamborn, et al. Radical Prostatectomy Without Prior Biopsy Following Multiparametric Magnetic Resonance Imaging and Prostate-specific Membrane Antigen Positron Emission Tomography. Eur Urol. In pr
    Eur Urol. 2022;81:e121.
    >> Share

    April 2022
  377. KISHAN AU, Wang X, Sun Y, Romero T, et al
    High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium.
    Eur Urol. 2022 Apr 22. pii: S0302-2838(22)01808.
    >> Share

  378. RAJWA P, Pradere B, Gandaglia G, van den Bergh RCN, et al
    Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis.
    Eur Urol. 2022 Apr 21. pii: S0302-2838(22)01802.
    >> Share

  379. GILLESSEN S, Armstrong A, Attard G, Beer TM, et al
    Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021.
    Eur Urol. 2022 Apr 18. pii: S0302-2838(22)01807.
    >> Share

  380. TURCO F, Armstrong A, Attard G, Beer TM, et al
    Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 2022].
    Eur Urol. 2022 Apr 16. pii: S0302-2838(22)01809.
    >> Share

  381. YU EY, Kolinsky MP, Berry WR, Retz M, et al
    Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study.
    Eur Urol. 2022 Apr 6. pii: S0302-2838(22)01665.
    >> Share

  382. THOMAN ME, Salari K
    Key Notes on Pembrolizumab and Docetaxel Combination Therapy for Metastatic Castration-Resistant Prostate Cancer.
    Eur Urol. 2022 Apr 5. pii: S0302-2838(22)01787.
    >> Share

  383. DI LORENZO G, Buonerba C
    Re: Matthew R. Smith, Maha Hussain, Fred Saad, et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med. In press. https://doi.org/10.1056/NEJMoa2119115.
    Eur Urol. 2022 Apr 4. pii: S0302-2838(22)01675.
    >> Share

  384. GAUTHE M, Sargos P, Benziane Ouaritini N, Barret E, et al
    Restaging of Patients with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy Using [(68)Ga]-PSMA-11 Positron Emission Tomography/Computed Tomography: Impact on Disease Management.
    Eur Urol. 2022;81:e87-e89.
    >> Share

  385. LEI Y, Zhang Y, Xing N
    Re: Cristina Masini, Cinzia Iotti, Ugo De Giorgi, et al. Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study. Eur Urol. 2022;81:274-82.
    Eur Urol. 2022;81:e96-e97.
    >> Share

  386. SOOD A, Jeong W, Palma-Zamora I, Abdollah F, et al
    Description of Surgical Technique and Oncologic and Functional Outcomes of the Precision Prostatectomy Procedure (IDEAL Stage 1-2b Study).
    Eur Urol. 2022;81:396-406.
    >> Share

    March 2022
  387. SHAH TT, Kanthabalan A, Otieno M, Pavlou M, et al
    Magnetic Resonance Imaging and Targeted Biopsies Compared to Transperineal Mapping Biopsies Before Focal Ablation in Localised and Metastatic Recurrent Prostate Cancer After Radiotherapy.
    Eur Urol. 2022 Mar 31. pii: S0302-2838(22)01664.
    >> Share

  388. HAO S, Heintz E, Ostensson E, Discacciati A, et al
    Corrigendum to "Cost-Effectiveness of the Stockholm3 Test and Magnetic Resonance Imaging in Prostate Cancer Screening: A Microsimulation Study" [Eur Urol 2022].
    Eur Urol. 2022 Mar 30. pii: S0302-2838(22)01796.
    >> Share

  389. NYAME YA, Cooperberg MR, Cumberbatch MG, Eggener SE, et al
    Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care.
    Eur Urol. 2022 Mar 30. pii: S0302-2838(22)01677.
    >> Share

  390. BJARTELL A
    Re: Performance of a Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography-derived Risk-stratification Tool for High-risk and Very High-risk Prostate Cancer.
    Eur Urol. 2022 Mar 29. pii: S0302-2838(22)01791.
    >> Share

  391. PUSHKAR D, Govorov A
    Re: Survival After Radical Prostatectomy Versus Radiation Therapy in High-risk and Very High-risk Prostate Cancer.
    Eur Urol. 2022 Mar 29. pii: S0302-2838(22)01794.
    >> Share

  392. WEI Y, Zhu Y, Ye D
    Re: Fabio Turco, Andrew Armstrong, Gerhardt Attard, et al. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. Eur Urol. In press. https://doi.org/10.101
    Eur Urol. 2022 Mar 28. pii: S0302-2838(22)01801.
    >> Share

  393. TURCO F, Smith M, Omlin A, Gillessen S, et al
    Reply to Yu Wei, Yao Zhu, and Dingwei Ye's Letter to the Editor re: Fabio Turco, Andrew Armstrong, Gerhardt Attard, et al. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Conse
    Eur Urol. 2022 Mar 28. pii: S0302-2838(22)01800.
    >> Share

  394. MARTINI A, Ploussard G
    Re: Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience.
    Eur Urol. 2022 Mar 25. pii: S0302-2838(22)01792.
    >> Share

  395. CHEN K, McVey A, Kasivisvanathan V, Jenjitranant P, et al
    Re: Darolutamide and Survival in Metastatic, Hormone-sensitive Prostate Cancer.
    Eur Urol. 2022 Mar 25. pii: S0302-2838(22)01789.
    >> Share

  396. WAGENSVELD IM, Osses DF, Groenendijk PM, Zijta FM, et al
    A Prospective Multicenter Comparison Study of Risk-adapted Ultrasound-directed and Magnetic Resonance Imaging-directed Diagnostic Pathways for Suspected Prostate Cancer in Biopsy-naive Men.
    Eur Urol. 2022 Mar 24. pii: S0302-2838(22)01673.
    >> Share

  397. KERKMEIJER LGW, Pos FJ, van der Heide UA, Israel B, et al
    Reply to Kamal Kant Sahu's Letter to the Editor re: Veerle H. Groen, Karin Haustermans, Floris J. Pos, et al. Patterns of Failure Following External Beam Radiotherapy With or Without an Additional Focal Boost in the Randomized Controlled FLAME Trial f
    Eur Urol. 2022 Mar 23. pii: S0302-2838(22)01674.
    >> Share

  398. DE BARROS HA, van Oosterom MN, Donswijk ML, Hendrikx JJMA, et al
    Robot-assisted Prostate-specific Membrane Antigen-radioguided Salvage Surgery in Recurrent Prostate Cancer Using a DROP-IN Gamma Probe: The First Prospective Feasibility Study.
    Eur Urol. 2022 Mar 23. pii: S0302-2838(22)01672.
    >> Share

  399. HEIDEGGER I, Pircher A
    Re: Qing Cheng, William Butler, Yinglu Zhou, et al. Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.12.039.
    Eur Urol. 2022 Mar 11. pii: S0302-2838(22)01667.
    >> Share

  400. NG A, Khetrapal P, Kasivisvanathan V
    Is It PRIME Time for Biparametric Magnetic Resonance Imaging in Prostate Cancer Diagnosis?
    Eur Urol. 2022 Mar 8. pii: S0302-2838(22)01663.
    >> Share

  401. VAN DER POEL H
    Re: Radical Prostatectomy for Localized Prostate Cancer: 20-Year Oncological Outcomes from a German High-volume Center.
    Eur Urol. 2022 Mar 2. pii: S0302-2838(22)01658.
    >> Share

    February 2022
  402. SAHU KK
    Re: Veerle H. Groen, Karin Haustermans, Floris J. Pos, et al. Patterns of Failure Following External Beam Radiotherapy With or Without an Additional Focal Boost in the Randomized Controlled FLAME Trial for Localized Prostate Cancer. Eur Urol. In press
    Eur Urol. 2022 Feb 26. pii: S0302-2838(22)01662.
    >> Share

  403. ZHOU J, Ding J, Qi J
    Comparison of Typical Prostate Adenocarcinoma and Rare Histological Variant Prostate Cancer Showed Different Characteristics and Prognosis: A Surveillance, Epidemiology, and End Results Database Analysis.
    Eur Urol. 2022 Feb 24. pii: S0302-2838(22)01645.
    >> Share

  404. ALI A, Baena E
    The Needle in the Haystack: The Presence of Castrate-resistant Prostate Cancer Cells in Hormone-naive Prostate Cancer.
    Eur Urol. 2022 Feb 24. pii: S0302-2838(22)01609.
    >> Share

  405. VICKERS AJ, Elfiky A, Freeman V, Roach M 3rd, et al
    Race, Biology, Disparities, and Prostate Cancer.
    Eur Urol. 2022 Feb 22. pii: S0302-2838(22)01646.
    >> Share

  406. GRUNWALD V, Ohlmann CH, Hadaschik B
    Re: Abiraterone Acetate and Prednisolone With or Without Enzalutamide for High-risk Non-metastatic Prostate Cancer: A Meta-analysis of Primary Results from Two Randomized Controlled Phase 3 Trials of the STAMPEDE Platform Protocol.
    Eur Urol. 2022 Feb 19. pii: S0302-2838(22)01648.
    >> Share

  407. BEYER K, Moris L, Lardas M, Omar MI, et al
    Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resistant Prostate Cancer: An Update from the PIONEER Consortium.
    Eur Urol. 2022 Feb 17. pii: S0302-2838(22)00085.
    >> Share

  408. TURCO F, Armstrong A, Attard G, Beer TM, et al
    What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021.
    Eur Urol. 2022 Feb 17. pii: S0302-2838(22)01650.
    >> Share

  409. MONTORSI F, Stabile A, Gandaglia G, Briganti A, et al
    Re: Jana S. Hopstaken, Joyce G.R. Bomers, Michiel J.P. Sedelaar, et al. An Updated Systematic Review on Focal Therapy in Localized Prostate Cancer: What Has Changed over the Past 5 Years? Eur Urol 2022;81:5-33.
    Eur Urol. 2022 Feb 9. pii: S0302-2838(22)00078.
    >> Share

  410. HEIJNSDIJK EAM, de Koning HJ
    Improved Harm/Benefit Ratio and Cost-effectiveness of Prostate Cancer Screening Using New Technologies.
    Eur Urol. 2022 Feb 4. pii: S0302-2838(22)00075.
    >> Share

  411. REDDY D, Peters M, Shah TT, van Son M, et al
    Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience.
    Eur Urol. 2022 Feb 2. pii: S0302-2838(22)00006.
    >> Share

  412. GODTMAN RA, Kollberg KS, Pihl CG, Mansson M, et al
    The Association Between Age, Prostate Cancer Risk, and Higher Gleason Score in a Long-term Screening Program: Results from the Goteborg-1 Prostate Cancer Screening Trial.
    Eur Urol. 2022 Feb 1. pii: S0302-2838(22)00019.
    >> Share

  413. SAAD F, Small EJ, Feng FY, Graff JN, et al
    Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN.
    Eur Urol. 2022;81:184-192.
    >> Share

  414. MAZZONE E, Gandaglia G, Ploussard G, Marra G, et al
    Risk Stratification of Patients Candidate to Radical Prostatectomy Based on Clinical and Multiparametric Magnetic Resonance Imaging Parameters: Development and External Validation of Novel Risk Groups.
    Eur Urol. 2022;81:193-203.
    >> Share

    January 2022
  415. ZUMSTEG ZS
    Simultaneous Integrated Micro-boost: Reigniting the FLAME for Dose Escalation in Prostate Cancer?
    Eur Urol. 2022 Jan 30. pii: S0302-2838(22)00064.
    >> Share

  416. BRAUN A, Abbosh PH
    Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy: A Rare Entity with Unique Genomic Features.
    Eur Urol. 2022 Jan 30. pii: S0302-2838(22)00067.
    >> Share

  417. MARKT SC, Penney KL, Schumacher FR
    Finding a Place for Family History To Inform High-grade Prostate Cancer Risk.
    Eur Urol. 2022 Jan 29. pii: S0302-2838(22)00066.
    >> Share

  418. RASLAN M, Mercader C, Lamb AD
    Re: Prostate Cancer Screening Using a Combination of Risk-prediction, MRI, and Targeted Prostate Biopsies (STHLM3-MRI): A Prospective, Population-based, Randomised, Open-label, Non-inferiority Trial.
    Eur Urol. 2022 Jan 29. pii: S0302-2838(22)00021.
    >> Share

  419. WALZ J
    Re: Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients with Localized Prostate Cancer: Results from the FLAME Randomized Phase III Trial.
    Eur Urol. 2022 Jan 29. pii: S0302-2838(22)00016.
    >> Share

  420. WITHINGTON J, Moore CM
    Active Surveillance for Prostate Cancer: Will Magnetic Resonance Imaging Help Us Address the Current Controversies in Traditional Surveillance Approaches?
    Eur Urol. 2022 Jan 28. pii: S0302-2838(22)00007.
    >> Share

  421. MASON MD, van der Kwast TH, Mottet N, Oprea-Lager DE, et al
    Modern Imaging in Prostate Cancer: Do We Treat Patients, or Their Scans?
    Eur Urol. 2022 Jan 27. pii: S0302-2838(22)00003.
    >> Share

  422. HAO S, Heintz E, Ostensson E, Discacciati A, et al
    Cost-Effectiveness of the Stockholm3 Test and Magnetic Resonance Imaging in Prostate Cancer Screening: A Microsimulation Study.
    Eur Urol. 2022 Jan 27. pii: S0302-2838(21)02269.
    >> Share

  423. DI LALLA V, Kucharczyk MJ, Wyatt AW, Feng FY, et al
    Quality and Quantity: Evaluating Tumor Biology Alongside Novel Imaging on Diagnosis of Metastatic Hormone-sensitive Prostate Cancer.
    Eur Urol. 2022 Jan 19. pii: S0302-2838(21)02287.
    >> Share

  424. CHENG Q, Butler W, Zhou Y, Zhang H, et al
    Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.
    Eur Urol. 2022 Jan 17. pii: S0302-2838(22)00001.
    >> Share

  425. DARST BF, Hughley R, Pfennig A, Hazra U, et al
    A Rare Germline HOXB13 Variant Contributes to Risk of Prostate Cancer in Men of African Ancestry.
    Eur Urol. 2022 Jan 11. pii: S0302-2838(21)02271.
    >> Share

  426. OZEN H, Turkeri L
    Re: Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-specific Mortality Results from the International Staging Collaboration for Cancer of the Prostate.
    Eur Urol. 2022 Jan 11. pii: S0302-2838(21)02277.
    >> Share

  427. DEVLIES W, Devos G, Decloedt H, Vansevenant B, et al
    Re: Molecular Features of Exceptional Response to Neoadjuvant Anti-androgen Therapy in High-risk Localized Prostate Cancer.
    Eur Urol. 2022 Jan 11. pii: S0302-2838(21)02275.
    >> Share

  428. SKOTHEIM RI, Axcrona U, Axcrona K
    Re: Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate Cancer.
    Eur Urol. 2022 Jan 11. pii: S0302-2838(21)02280.
    >> Share

  429. GREENBERG SE, Jacobs MF
    Continuing the Evolution of Germline Genetics in Prostate Cancer: Tailoring Testing To Enhance Patient Care.
    Eur Urol. 2022 Jan 10. pii: S0302-2838(21)02268.
    >> Share

  430. FLESHNER K, Carlsson SV
    Re: Changes in Prostate-specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening.
    Eur Urol. 2022 Jan 10. pii: S0302-2838(21)02276.
    >> Share

  431. SINGH J
    Re: Marc Sbizzera, Nicolas Morel-Journal, Alain Ruffion, et al. Rectourethral Fistula Induced by Localised Prostate Cancer Treatment: Surgical and Functional Outcomes of Transperineal Repair with Gracilis Muscle Flap Interposition. Eur Urol. In press.
    Eur Urol. 2022 Jan 7. pii: S0302-2838(21)02210.
    >> Share

  432. MOROTE J, Diaz F, Celma A, Planas J, et al
    Behavior of SelectMDx and Prostate-specific Antigen Density in the Challenging Scenario of Prostate Imaging-Reporting and Data System Category 3 Lesions.
    Eur Urol. 2022;81:124-125.
    >> Share

  433. HOFMANN M, Huang E, Huynh LM, Kaler K, et al
    Retrospective Concomitant Nonrandomized Comparison of "Touch" Cautery Versus Athermal Dissection of the Prostatic Vascular Pedicles and Neurovascular Bundles During Robot-assisted Radical Prostatectomy.
    Eur Urol. 2022;81:104-109.
    >> Share

    December 2021
  434. CLEMENTS MB, Vertosick EA, Guerrios-Rivera L, De Hoedt AM, et al
    Defining the Impact of Family History on Detection of High-grade Prostate Cancer in a Large Multi-institutional Cohort.
    Eur Urol. 2021 Dec 31. pii: S0302-2838(21)02222.
    >> Share

  435. WILLEMSE PM, Davis NF, Grivas N, Zattoni F, et al
    Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy.
    Eur Urol. 2021 Dec 31. pii: S0302-2838(21)02215.
    >> Share

  436. GROEN VH, Haustermans K, Pos FJ, Draulans C, et al
    Patterns of Failure Following External Beam Radiotherapy With or Without an Additional Focal Boost in the Randomized Controlled FLAME Trial for Localized Prostate Cancer.
    Eur Urol. 2021 Dec 22. pii: S0302-2838(21)02223.
    >> Share

  437. MOSSANEN M, Carvalho FLF, Muralidhar V, Preston MA, et al
    Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy.
    Eur Urol. 2021 Dec 22. pii: S0302-2838(21)02212.
    >> Share

  438. SBIZZERA M, Morel-Journel N, Carnicelli D, Ruffion A, et al
    Reply to Jas Singh's Letter to the Editor re: Marc Sbizzera, Nicolas Morel-Journel, Alain Ruffion, et al. Rectourethral Fistula Induced by Localised Prostate Cancer Treatment: Surgical and Functional Outcomes of Transperineal Repair with Gracilis Musc
    Eur Urol. 2021 Dec 18. pii: S0302-2838(21)02209.
    >> Share

  439. GRUMMET J, Eggener S
    Re: NCCN Prostate Cancer Guidelines Version 1.2022 - September 10, 2021.
    Eur Urol. 2021 Dec 9. pii: S0302-2838(21)02201.
    >> Share

  440. CASTRO E
    TP53: Another Piece of the Prostate Cancer Genetics Puzzle.
    Eur Urol. 2021 Dec 9. pii: S0302-2838(21)02199.
    >> Share

  441. FASULO V, Zuradelli M, Lazzeri M
    Re: A Prospective Prostate Cancer Screening Programme for Men with Pathogenic Variants in Mismatch Repair Genes (IMPACT): Initial Results from an International Prospective Study.
    Eur Urol. 2021 Dec 9. pii: S0302-2838(21)02206.
    >> Share

  442. SWAMI U, Sayegh N, Agarwal N
    Development of Novel Regimens Combining Immune Checkpoint Inhibitors and Radiation Therapy in Prostate Cancer.
    Eur Urol. 2021 Dec 8. pii: S0302-2838(21)02200.
    >> Share

  443. MAXWELL KN, Cheng HH, Powers J, Gulati R, et al
    Inherited TP53 Variants and Risk of Prostate Cancer.
    Eur Urol. 2021 Dec 1. pii: S0302-2838(21)02139.
    >> Share

  444. ROCCO B, Sarchi L, Assumma S, Cimadamore A, et al
    Digital Frozen Sections with Fluorescence Confocal Microscopy During Robot-assisted Radical Prostatectomy: Surgical Technique.
    Eur Urol. 2021;80:724-729.
    >> Share

    November 2021
  445. NGUYEN AT, Kamrava M
    Re: Jana S. Hopstaken, Joyce G.R. Bomers, Michiel J.P. Sedelaar, Massimo Valerio, Jurgen J. Futterer, Maroeska M. Rovers. An Updated Systematic Review on Focal Therapy in Localized Prostate Cancer: What Has Changed over the Past 5 Years? Eur Urol. In
    Eur Urol. 2021 Nov 27. pii: S0302-2838(21)02159.
    >> Share

  446. LANTZ A, Bock D, Akre O, Angenete E, et al
    Reply to Wei Zhang So, Ziting Wang, and Ho Yee Tiong's Letter to the Editor re: Anna Lantz, David Bock, Olof Akre, et al. Functional and Oncological Outcomes After Open Versus Robot-assisted Laparoscopic Radical Prostatectomy for Localised Prostate Ca
    Eur Urol. 2021 Nov 24. pii: S0302-2838(21)02150.
    >> Share

  447. WILT TJ, Vo TN, Langsetmo L, Dahm P, et al
    Corrigendum re: "Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT)" [Eur Urol 2020;77:713-24].
    Eur Urol. 2021 Nov 23. pii: S0302-2838(21)02157.
    >> Share

  448. SO WZ, Wang Z, Tiong HY
    Re: Anna Lantz, David Bock, Olof Akre, et al. Functional and Oncological Outcomes After Open Versus Robot-assisted Laparoscopic Radical Prostatectomy for Localised Prostate Cancer: 8-Year Follow-up. Eur Urol 2021;80:650-60.
    Eur Urol. 2021 Nov 22. pii: S0302-2838(21)02140.
    >> Share

  449. IMMERZEEL J, Israel B, Bomers J, Schoots IG, et al
    Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 4: Transperineal Magnetic Resonance-Ultrasound Fusion Guided Biopsy Using Local Anesthesia.
    Eur Urol. 2021 Nov 16. pii: S0302-2838(21)02135.
    >> Share

  450. BACIARELLO G, Delva R, Gravis G, Tazi Y, et al
    Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial.
    Eur Urol. 2021 Nov 14. pii: S0302-2838(21)02117.
    >> Share

  451. PANSADORO V, Brassetti A
    Re: Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histolo
    Eur Urol. 2021 Nov 13. pii: S0302-2838(21)02125.
    >> Share

  452. SCHMID HP, Hechelhammer L, Mullhaupt G
    Re: Early Results of Unilateral Prostatic Artery Embolization as a Focal Therapy in Patients with Prostate Cancer Under Active Surveillance: Cancer Prostate Embolisation, a Pilot Study.
    Eur Urol. 2021 Nov 9. pii: S0302-2838(21)02128.
    >> Share

  453. DE KOUCHKOVSKY I, Chen HY, Ohliger MA, Wang ZJ, et al
    Hyperpolarized 1-[(13)C]-Pyruvate Magnetic Resonance Imaging Detects an Early Metabolic Response to Immune Checkpoint Inhibitor Therapy in Prostate Cancer.
    Eur Urol. 2021 Nov 7. pii: S0302-2838(21)02116.
    >> Share

  454. BELTRAN H, Morgans AK
    Leveraging Real World Genomic Data to Advance Prostate Cancer Precision Oncology.
    Eur Urol. 2021 Nov 3. pii: S0302-2838(21)02131.
    >> Share

  455. ABREU AL, Kaneko M, Cacciamani GE, Lebastchi AH, et al
    Focal Therapy for Prostate Cancer: Getting Ready for Prime Time.
    Eur Urol. 2021 Nov 2. pii: S0302-2838(21)02073.
    >> Share

  456. KAZYBAY B, Xie Y
    Re: Herjan J.T. Coelingh Bennink, Jean-Michel Foidart, Frans M.J. Debruyne. Treatment of Serious COVID-19 with Testosterone Suppression and High-dose Estrogen Therapy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.06.024.
    Eur Urol. 2021;80:e115-e116.
    >> Share

  457. COELINGH BENNINK HJT, Foidart JM, Debruyne FMJ
    Reply to Bexultan Kazybay and Yingqiu Xie's Letter to the Editor re: Herjan J.T. Coelingh Bennink, Jean-Michel Foidart, Frans M.J. Debruyne. Treatment of Serious COVID-19 with Testosterone Suppression and High-dose Estrogen Therapy. Eur Urol. In press
    Eur Urol. 2021;80:e117-e118.
    >> Share

    October 2021
  458. VAN POPPEL H, Roobol MJ
    Reply to Takeshi Takahashi's Letter to the Editor re: Hendrik Van Poppel, Monique J. Roobol, Christopher R. Chapple, et al. Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association
    Eur Urol. 2021 Oct 28. pii: S0302-2838(21)02072.
    >> Share

  459. TAKAHASHI T
    Re: Hendrik Van Poppel, Monique J. Roobol, Christopher R. Chapple, et al. Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021.
    Eur Urol. 2021 Oct 26. pii: S0302-2838(21)02071.
    >> Share

  460. GRAF RP, Fisher V, Mateo J, Gjoerup OV, et al
    Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2021 Oct 26. pii: S0302-2838(21)02060.
    >> Share

  461. LEE DJ, Hausler R, Le AN, Kelly G, et al
    Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer.
    Eur Urol. 2021 Oct 25. pii: S0302-2838(21)02059.
    >> Share

  462. SBIZZERA M, Morel-Journel N, Ruffion A, Crouzet S, et al
    Rectourethral Fistula Induced by Localised Prostate Cancer Treatment: Surgical and Functional Outcomes of Transperineal Repair with Gracilis Muscle Flap Interposition.
    Eur Urol. 2021 Oct 19. pii: S0302-2838(21)02041.
    >> Share

  463. OST P, Siva S, Zilli T
    Everything But the Kitchen Sink: Comprehensive Nodal Irradiation with Androgen Deprivation in OLIGOPELVIS.
    Eur Urol. 2021;80:415-416.
    >> Share

  464. BIANCHI L, Chessa F, Angiolini A, Cercenelli L, et al
    The Use of Augmented Reality to Guide the Intraoperative Frozen Section During Robot-assisted Radical Prostatectomy.
    Eur Urol. 2021;80:480-488.
    >> Share

  465. WURNSCHIMMEL C, Pose RM, Wenzel M, Tian Z, et al
    Validation of the STAR-CAP Clinical Prognostic System for Predicting Biochemical Recurrence, Metastasis, and Cancer-specific Mortality After Radical Prostatectomy in a European Cohort.
    Eur Urol. 2021;80:400-404.
    >> Share

    September 2021
  466. VICKERS AJ
    Reply to Francesco Montorsi, Giorgio Gandaglia, and Alberto Briganti's Letter to the Editor re: Andrew J. Vickers. Effects of Magnetic Resonance Imaging Targeting on Overdiagnosis and Overtreatment of Prostate Cancer. Eur Urol. In press. https://doi.o
    Eur Urol. 2021 Sep 29. pii: S0302-2838(21)02050.
    >> Share

  467. MONTORSI F, Gandaglia G, Briganti A
    Re: Andrew J. Vickers. Effects of Magnetic Resonance Imaging Targeting on Overdiagnosis and Overtreatment of Prostate Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.06.026.
    Eur Urol. 2021 Sep 28. pii: S0302-2838(21)02051.
    >> Share

  468. REN S, Yang B, Wang D
    Re: Vicenc Ruiz de Porras, Xieng C. Wang, Luis Palomero, et al. Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment. Eur Urol 2021;79:722-33.
    Eur Urol. 2021 Sep 25. pii: S0302-2838(21)02018.
    >> Share

  469. TRELLES CR, Martinez-Pineiro L
    Re: The Role of Cytoreductive Radical Prostatectomy in the Treatment of Newly Diagnosed Low-volume Metastatic Prostate Cancer. Results from the Local Treatment of Metastatic Prostate Cancer (LoMP) Registry.
    Eur Urol. 2021 Sep 24. pii: S0302-2838(21)02000.
    >> Share

  470. HAGENS MJ, van Leeuwen PJ
    A Future Prebiopsy Imaging-guided Pathway to Safely Omit Systematic Biopsies and Prevent Diagnosis of Indolent Prostate Cancer.
    Eur Urol. 2021 Sep 21. pii: S0302-2838(21)02002.
    >> Share

  471. LANTZ A, Bock D, Akre O, Angenete E, et al
    Functional and Oncological Outcomes After Open Versus Robot-assisted Laparoscopic Radical Prostatectomy for Localised Prostate Cancer: 8-Year Follow-up.
    Eur Urol. 2021 Sep 15. pii: S0302-2838(21)01928.
    >> Share

  472. GHALI F, Kane CJ
    Re: Association of Black Race with Prostate Cancer-specific and Other-cause Mortality.
    Eur Urol. 2021 Sep 14. pii: S0302-2838(21)01999.
    >> Share

  473. ALAN MCNEILL S, Gallagher KM, Clyde D
    Re: A Biochemical Definition of Cure After Brachytherapy for Prostate Cancer.
    Eur Urol. 2021 Sep 13. pii: S0302-2838(21)01995.
    >> Share

  474. SHOAG JE, Hill A, Jung JH, Spratt D, et al
    Re: Safety and Efficacy of Virtual Prostatectomy with Single-dose Radiotherapy in Patients with Intermediate-risk Prostate Cancer: Results from the PROSINT Phase 2 Randomized Clinical Trial.
    Eur Urol. 2021 Sep 10. pii: S0302-2838(21)01988.
    >> Share

  475. KWAN EM, Spain L, Anton A, Gan CL, et al
    Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial.
    Eur Urol. 2021 Sep 4. pii: S0302-2838(21)01979.
    >> Share

  476. THURTLE D, Jenkins V, Freeman A, Pearson M, et al
    Clinical Impact of the Predict Prostate Risk Communication Tool in Men Newly Diagnosed with Nonmetastatic Prostate Cancer: A Multicentre Randomised Controlled Trial.
    Eur Urol. 2021 Sep 4. pii: S0302-2838(21)01933.
    >> Share

  477. HOPSTAKEN JS, Bomers JGR, Sedelaar MJP, Valerio M, et al
    An Updated Systematic Review on Focal Therapy in Localized Prostate Cancer: What Has Changed over the Past 5 Years?
    Eur Urol. 2021 Sep 3. pii: S0302-2838(21)01949.
    >> Share

  478. LIU W, Zukotynski K, Bauman G
    Re: Rachel M. Glicksman, Ur Metser, Douglass Vines, et al. Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. Eur Urol 2021;80:374-
    Eur Urol. 2021;80:e77-e78.
    >> Share

    August 2021
  479. EMMETT L, Buteau J, Papa N, Moon D, et al
    The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study.
    Eur Urol. 2021 Aug 28. pii: S0302-2838(21)01946.
    >> Share

  480. VAN POPPEL H, Roobol MJ, Chapple CR, Catto JWF, et al
    Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021.
    Eur Urol. 2021 Aug 15. pii: S0302-2838(21)01927.
    >> Share

  481. LORENTE D, Llacer C, Lozano R, de Velasco G, et al
    Prognostic Score and Benefit from Abiraterone in First-line Metastatic, Castration-resistant Prostate Cancer.
    Eur Urol. 2021 Aug 6. pii: S0302-2838(21)01917.
    >> Share

  482. VENTIMIGLIA E, Pozzi E, Alfano M, Montorsi F, et al
    Re: Scott D. Lundy, Naseer Sangwan, Neel V. Parekh, et al. Functional and Taxonomic Dysbiosis of the Gut, Urine, and Semen Microbiomes in Male Infertility. Eur Urol 2021;79:826-36.
    Eur Urol. 2021;80:e53-e54.
    >> Share

  483. GUPTA S, Pitel BA, Knight SM, Halling KC, et al
    Re: Stanley Weng, Renzo G. DiNatale, Andrew Silagy, et al. The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management. Eur Urol 2021;79:468-77.
    Eur Urol. 2021;80:e62-e63.
    >> Share

  484. LUNDY SD, Vij SC, Eng C
    Reply to Eugenio Ventimiglia, Edoardo Pozzi, Massimo Alfano, Francesco Montorsi, and Andrea Salonia's Letter to the Editor re: Scott D. Lundy, Naseer Sangwan, Neel V. Parekh, et al. Functional and Taxonomic Dysbiosis of the Gut, Urine, and Semen Micro
    Eur Urol. 2021;80:e55-e56.
    >> Share

  485. MEIJER D, van Leeuwen PJ, Roberts MJ, Siriwardana AR, et al
    External Validation and Addition of Prostate-specific Membrane Antigen Positron Emission Tomography to the Most Frequently Used Nomograms for the Prediction of Pelvic Lymph-node Metastases: an International Multicenter Study.
    Eur Urol. 2021;80:234-242.
    >> Share

  486. ROBINSON AG, Izard JP, Vera-Badillo FE
    Treatment and Patient Selection for Patients with Metastatic Castration-resistant Prostate After Progression on Docetaxel and Abiraterone/Enzalutamide: When to Play Your CARD and When to Do Your PARP.
    Eur Urol. 2021;80:123-126.
    >> Share

  487. WAGASKAR VG, Mittal A, Sobotka S, Ratnani P, et al
    Hood Technique for Robotic Radical Prostatectomy-Preserving Periurethral Anatomical Structures in the Space of Retzius and Sparing the Pouch of Douglas, Enabling Early Return of Continence Without Compromising Surgical Margin Rates.
    Eur Urol. 2021;80:213-221.
    >> Share

    July 2021
  488. HADASCHIK B, Herrmann K
    Re: Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
    Eur Urol. 2021 Jul 23. pii: S0302-2838(21)01885.
    >> Share

  489. VICKERS AJ
    Effects of Magnetic Resonance Imaging Targeting on Overdiagnosis and Overtreatment of Prostate Cancer.
    Eur Urol. 2021 Jul 19. pii: S0302-2838(21)01867.
    >> Share

  490. STERNBERG CN, Castellano D, de Bono J, Fizazi K, et al
    Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study.
    Eur Urol. 2021 Jul 14. pii: S0302-2838(21)01862.
    >> Share

  491. ATTARD G, Brown LC, Clarke NW, Parmar MKB, et al
    Should Patients with High-risk Localised or Locally Advanced Prostate Cancer Receive Abiraterone Acetate in Addition to Androgen Deprivation Therapy? Update on a Planned Analysis of the STAMPEDE Trial.
    Eur Urol. 2021 Jul 14. pii: S0302-2838(21)01864.
    >> Share

  492. SUPIOT S, Vaugier L, Pasquier D, Buthaud X, et al
    OLIGOPELVIS GETUG P07, a Multicenter Phase II Trial of Combined High-dose Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Node Relapses in Prostate Cancer.
    Eur Urol. 2021 Jul 8. pii: S0302-2838(21)01816.
    >> Share

  493. MARSDEN T, Ahmed HU, Emberton M
    An update from the ReIMAGINE Prostate Cancer Risk Study (NCT04060589): A prospective cohort study in men with a suspicion of prostate cancer who are referred onto a magnetic resonance imaging-based diagnostic pathway with donation of tissue, blood, an
    Eur Urol. 2021 Jul 1. pii: S0302-2838(21)01817.
    >> Share

  494. BERGOUGNOUX A, Ea V, Paris F, Kalfa N, et al
    Reply to Zhongzhong Chen, Hua Xie, and Fang Chen's Letter to the Editor re: Vuthy Ea, Anne Bergougnoux, Pascal Philibert, et al. How Far Should We Explore Hypospadias? Next-generation Sequencing Applied to a Large Cohort of Hypospadiac Patients. Eur U
    Eur Urol. 2021;80:e12-e13.
    >> Share

  495. CHEN Z, Xie H, Chen F
    Re: Vuthy Ea, Anne Bergougnoux, Pascal Philibert, et al. How Far Should We Explore Hypospadias? Next-generation Sequencing Applied to a Large Cohort of Hypospadiac Patients. Eur Urol 2021;79:507-515.
    Eur Urol. 2021;80:e10-e11.
    >> Share

    June 2021
  496. SATAPATHY S, Das N, Sood A, Goyal S, et al
    Short-course (177)Lu-PSMA-617 Radioligand Therapy in High-volume Metastatic Hormone-sensitive Prostate Cancer: Time to Take the Leap?
    Eur Urol. 2021 Jun 23. pii: S0302-2838(21)01818.
    >> Share

  497. SHARMA V, Karnes RJ
    Re: Prostate-specific Membrane Antigen PET-CT in Patients with High-risk Prostate Cancer Before Curative-intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomised, Multicentre Study.
    Eur Urol. 2021 Jun 23. pii: S0302-2838(21)01806.
    >> Share

  498. GLICKSMAN RM, Berlin A
    Reply to Wei Liu, Katherine Zukotynski, and Glenn Bauman's Letter to the Editor re: Rachel M. Glicksman, Ur Metser, Douglass Vines, et al. Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospect
    Eur Urol. 2021 Jun 19. pii: S0302-2838(21)01810.
    >> Share

  499. CIMADAMORE A, Cheng L, Lopez-Beltran A, Scarpelli M, et al
    Re: Scott Wilkinson, Huihui Ye, Fatima Karzai, et al. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.03.009: Focus on Intraductal Carcinoma o
    Eur Urol. 2021 Jun 17. pii: S0302-2838(21)01807.
    >> Share

  500. WILKINSON S, Ye H, Lis RT, Sowalsky AG, et al
    Reply to Alessia Cimadamore, Liang Cheng, Antonio Lopez-Beltran, Marina Scarpelli, and Rodolfo Montironi's Letter to the Editor re: Scott Wilkinson, Huihui Ye, Fatima Karzai, et al. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance
    Eur Urol. 2021 Jun 17. pii: S0302-2838(21)01808.
    >> Share

  501. GHADJAR P, Hayoz S, Bernhard J, Zwahlen DR, et al
    Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial.
    Eur Urol. 2021 Jun 14. pii: S0302-2838(21)01802.
    >> Share

  502. TILKI D, Evans CP
    Re: Regional Adoption of Commercial Gene Expression Testing for Prostate Cancer.
    Eur Urol. 2021 Jun 9. pii: S0302-2838(21)01805.
    >> Share

  503. SUMANASURIYA S, Seed G, Parr H, Christova R, et al
    Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA.
    Eur Urol. 2021 Jun 5. pii: S0302-2838(21)01799.
    >> Share

  504. CHOW AK, Vourganti S, Konety BR
    Re: Oral Relugolix for Androgen-deprivation Therapy in Advanced Prostate Cancer.
    Eur Urol. 2021 Jun 3. pii: S0302-2838(21)01796.
    >> Share

  505. CIMADAMORE A, Lopez-Beltran A, Scarpelli M, Montironi R, et al
    Re: Timothy D. Jones, Liang Cheng. Histologic Grading of Bladder Tumors: Using Both the 1973 and 2004/2016 World Health Organization Systems in Combination Provides Valuable Information for Establishing Prognostic Risk Groups. Eur Urol 2021;79:489-91.
    Eur Urol. 2021;79:e172-e173.
    >> Share

  506. JONES TD, Cheng L
    Reply to Alessia Cimadamore, Antonio Lopez-Beltran, Marina Scarpelli, and Rodolfo Montironi's Letter to the Editor re: Timothy D. Jones, Liang Cheng. Histologic Grading of Bladder Tumors: Using Both the 1973 and 2004/2016 World Health Organization Sys
    Eur Urol. 2021;79:e174-e175.
    >> Share

  507. GUO C, Crespo M, Gurel B, Dolling D, et al
    CD38 in Advanced Prostate Cancers.
    Eur Urol. 2021;79:736-746.
    >> Share

  508. STOLZENBURG JU, Holze S, Neuhaus P, Kyriazis I, et al
    Robotic-assisted Versus Laparoscopic Surgery: Outcomes from the First Multicentre, Randomised, Patient-blinded Controlled Trial in Radical Prostatectomy (LAP-01).
    Eur Urol. 2021;79:750-759.
    >> Share

  509. EGAN J, Marhamati S, Carvalho FLF, Davis M, et al
    Retzius-sparing Robot-assisted Radical Prostatectomy Leads to Durable Improvement in Urinary Function and Quality of Life Versus Standard Robot-assisted Radical Prostatectomy Without Compromise on Oncologic Efficacy: Single-surgeon Series and Step-by-
    Eur Urol. 2021;79:839-857.
    >> Share

    May 2021
  510. SATISH P, Simpson B, Freeman A, Giganti F, et al
    Mapping Contemporary Biopsy Zones to Traditional Prostatic Anatomy: The Key to Understanding Relationships Between Prostate Cancer Topography, Magnetic Resonance Imaging Conspicuity, and Clinical Risk.
    Eur Urol. 2021 May 28. pii: S0302-2838(21)00355.
    >> Share

  511. LIAUW SL
    High-risk Prostate Cancer Treated with Radiation Therapy: Opportunities to Reduce Cancer Mortality after Biochemical Failure.
    Eur Urol. 2021 May 27. pii: S0302-2838(21)00392.
    >> Share

  512. PADHANI AR, Rouviere O, Schoots IG
    Magnetic Resonance Imaging for Tailoring the Need to Biopsy During Follow-up for Men on Active Surveillance for Prostate Cancer.
    Eur Urol. 2021 May 27. pii: S0302-2838(21)00393.
    >> Share

  513. SWEENEY CJ, Martin AJ, Stockler MR, Begbie S, et al
    Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy.
    Eur Urol. 2021 May 21. pii: S0302-2838(21)00354.
    >> Share

  514. XU J, Isaacs WB
    Incorporation of Polygenic Risk Score into Guidelines for Inherited Risk Assessment for Prostate Cancer.
    Eur Urol. 2021 May 20. pii: S0302-2838(21)00323.
    >> Share

  515. RAJWA P, Pradere B, Quhal F, Mori K, et al
    Reliability of Serial Prostate Magnetic Resonance Imaging to Detect Prostate Cancer Progression During Active Surveillance: A Systematic Review and Meta-analysis.
    Eur Urol. 2021 May 18. pii: S0302-2838(21)00325.
    >> Share

  516. PHILIPSON RG, Romero T, Wong JK, Stish BJ, et al
    Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer.
    Eur Urol. 2021 May 10. pii: S0302-2838(21)00314.
    >> Share

  517. CHENG HH
    Molecular Subtyping in the Neoadjuvant Setting in Prostate Cancer: Envisioning the Possibilities.
    Eur Urol. 2021 May 7. pii: S0302-2838(21)00308.
    >> Share

  518. VAN POPPEL H, Hogenhout R, Albers P, van den Bergh RCN, et al
    Reply to Laura Evangelista and Egesta Lopci's Letter to the Editor re: Hendrik Van Poppel, Renee Hogenhout, Peter Albers, et al. Early Detection of Prostate Cancer in 2020 and Beyond: Facts and Recommendations for the European Union and the European C
    Eur Urol. 2021 May 5. pii: S0302-2838(21)00297.
    >> Share

  519. VAN DEN BROECK T, Oprea-Lager D, Moris L, Kailavasan M, et al
    A Systematic Review of the Impact of Surgeon and Hospital Caseload Volume on Oncological and Nononcological Outcomes After Radical Prostatectomy for Nonmetastatic Prostate Cancer.
    Eur Urol. 2021 May 4. pii: S0302-2838(21)00298.
    >> Share

  520. EVANGELISTA L, Lopci E
    Re: Hendrik Van Poppel, Renee Hogenhout, Peter Albers, et al. Early Detection of Prostate Cancer in 2020 and Beyond: Facts and Recommendations for the European Union and the European Commission. Eur Urol 2021;79:327-9: Early Detection of Prostate Canc
    Eur Urol. 2021 May 1. pii: S0302-2838(21)00296.
    >> Share

  521. DARST BF, Sheng X, Eeles RA, Kote-Jarai Z, et al
    Combined Effect of a Polygenic Risk Score and Rare Genetic Variants on Prostate Cancer Risk.
    Eur Urol. 2021 May 1. pii: S0302-2838(21)00253.
    >> Share

  522. REITBLAT C, Bain PA, Porter ME, Bernstein DN, et al
    Value-Based Healthcare in Urology: A Collaborative Review.
    Eur Urol. 2021;79:571-585.
    >> Share

  523. SUNDAHL N, Gillessen S, Sweeney C, Ost P, et al
    When What You See Is Not Always What You Get: Raising the Bar of Evidence for New Diagnostic Imaging Modalities.
    Eur Urol. 2021;79:565-567.
    >> Share

    April 2021
  524. KIM SE, Shin JI, Shoag JE
    Re: Luca F. Valle, Eric J. Lehrer, Daniela Markovic, et al. A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.11.010.
    Eur Urol. 2021 Apr 30. pii: S0302-2838(21)00251.
    >> Share

  525. VALLE LF, Kishan AU
    Reply to Sungeun Kim, Jae Il Shin, and Jonathan Evan Shoag's Letter to the Editor re: Luca F. Valle, Eric J. Lehrer, Daniela Markovic, et al. A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MAST
    Eur Urol. 2021 Apr 29. pii: S0302-2838(21)00250.
    >> Share

  526. BERCHUCK JE, Zhang Z, Silver R, Kwak L, et al
    Impact of Pathogenic Germline DNA Damage Repair alterations on Response to Intense Neoadjuvant Androgen Deprivation Therapy in High-risk Localized Prostate Cancer.
    Eur Urol. 2021 Apr 19. pii: S0302-2838(21)00237.
    >> Share

  527. ADELEKE S, Haroon A, Kasivisvanathan V
    Re: [(177)Lu]Lu-PSMA-617 Versus Cabazitaxel in Patients with Metastatic Castration-resistant Prostate Cancer (TheraP): A Randomised, Open-label, Phase 2 Trial.
    Eur Urol. 2021 Apr 16. pii: S0302-2838(21)00245.
    >> Share

  528. CHU CE, Alshalalfa M, Sjostrom M, Zhao SG, et al
    Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer.
    Eur Urol. 2021 Apr 8. pii: S0302-2838(21)00215.
    >> Share

  529. SADAGHIANI MS, Sheikhbahaei S, Werner RA, Pienta KJ, et al
    A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
    Eur Urol. 2021 Apr 8. pii: S0302-2838(21)00175.
    >> Share

  530. PIAZZA P, Rosiello G, Chacon VT, Puliatti S, et al
    Robot-assisted Cystectomy with Intracorporeal Urinary Diversion After Pelvic Irradiation for Prostate Cancer: Technique and Results from a Single High-volume Center.
    Eur Urol. 2021 Apr 7. pii: S0302-2838(21)00229.
    >> Share

  531. OKE O, Ranasinghe W, Tang C, Shaaban S, et al
    Impact of Definitive Local Therapy in Men with Primary Small Cell Prostate Carcinoma.
    Eur Urol. 2021 Apr 3. pii: S0302-2838(21)00228.
    >> Share

  532. FICARRA V, Rossanese M, Crestani A, Alario G, et al
    Robot-assisted Radical Prostatectomy Using the Novel Urethral Fixation Technique Versus Standard Vesicourethral Anastomosis.
    Eur Urol. 2021;79:530-536.
    >> Share

  533. GIGANTI F, Kasivisvanathan V, Allen C, Moore CM, et al
    The Importance of Being PRECISE in Prostate Magnetic Resonance Imaging and Active Surveillance.
    Eur Urol. 2021;79:560-563.
    >> Share

  534. HAMILTON RJ, Ding K, Crook JM, O'Callaghan CJ, et al
    The Association Between Statin Use and Outcomes in Patients Initiating Androgen Deprivation Therapy.
    Eur Urol. 2021;79:446-452.
    >> Share

  535. KNIPPER S, Ascalone L, Ziegler B, Hohenhorst JL, et al
    Salvage Surgery in Patients with Local Recurrence After Radical Prostatectomy.
    Eur Urol. 2021;79:537-544.
    >> Share

  536. GIANNARINI G, Valotto C, Girometti R, Dal Moro F, et al
    Measuring the Quality of Diagnostic Prostate Magnetic Resonance Imaging: A Urologist's Perspective.
    Eur Urol. 2021;79:440-441.
    >> Share

    March 2021
  537. MOSCHOVAS MC, Bhat S, Sandri M, Rogers T, et al
    Comparing the Approach to Radical Prostatectomy Using the Multiport da Vinci Xi and da Vinci SP Robots: A Propensity Score Analysis of Perioperative Outcomes.
    Eur Urol. 2021;79:393-404.
    >> Share

  538. LENFANT L, Garisto J, Sawczyn G, Wilson CA, et al
    Robot-assisted Radical Prostatectomy Using Single-port Perineal Approach: Technique and Single-surgeon Matched-paired Comparative Outcomes.
    Eur Urol. 2021;79:384-392.
    >> Share

    February 2021
  539. ROSIELLO G, Piazza P, Tames V, Farinha R, et al
    The Impact of Previous Prostate Surgery on Surgical Outcomes for Patients Treated with Robot-assisted Radical Cystectomy for Bladder Cancer.
    Eur Urol. 2021 Feb 27. pii: S0302-2838(21)00149.
    >> Share

  540. RANASINGHE W, Shapiro DD, Hwang H, Wang X, et al
    Ductal Prostate Cancers Demonstrate Poor Outcomes with Conventional Therapies.
    Eur Urol. 2021;79:298-306.
    >> Share

  541. HU JC, Basourakos SP, Futterer J
    Need for Systematic Magnetic Resonance Imaging Interpretation and Reporting after Partial Prostate Gland Ablation.
    Eur Urol. 2021;79:167-169.
    >> Share

    January 2021
  542. VAN DIJK N, Gomez de Liano Lista A, Szabados B, Powles T, et al
    Reply to Alessia Cimadamore, Liang Cheng, Marina Scarpelli, et al's Letter to the Editor re: Alfonso Gomez de Liano Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Anti-P
    Eur Urol. 2021;79:e20-e21.
    >> Share

  543. KYPRIANOU N
    Re: Regenerative Potential of Prostate Luminal Cells Revealed by Single-cell Analysis.
    Eur Urol. 2021;79:161-162.
    >> Share

  544. MORGANS AK
    Minimizing Risk to Maximize Outcomes.
    Eur Urol. 2021;79:54-55.
    >> Share

  545. CHEN Y, Wang Z, Liu J
    Re: Giovanni Lavorgna, Riccardo Vago, Francesco Montorsi, Andrea Salonia. Surnames in Y-Chromosome-related Diseases: A New Tool for the Urologist? Eur Urol 2020;77:767-8.
    Eur Urol. 2021;79:e37.
    >> Share

  546. DELL'OGLIO P, Meershoek P, Maurer T, Wit EMK, et al
    A DROP-IN Gamma Probe for Robot-assisted Radioguided Surgery of Lymph Nodes During Radical Prostatectomy.
    Eur Urol. 2021;79:124-132.
    >> Share

  547. STAVRINIDES V, Syer T, Hu Y, Giganti F, et al
    False Positive Multiparametric Magnetic Resonance Imaging Phenotypes in the Biopsy-naive Prostate: Are They Distinct from Significant Cancer-associated Lesions? Lessons from PROMIS.
    Eur Urol. 2021;79:20-29.
    >> Share

    November 2020
  548. IYER G, Bochner BH, Van Allen EM, Solit DB, et al
    Re: Russell E.N. Becker, Alexa R. Meyer, Aaron Brant, et al. Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eu
    Eur Urol. 2020 Nov 17. pii: S0302-2838(20)30865.
    >> Share

  549. BECKER REN, Baras A, Bivalacqua TJ
    Reply to Gopa Iyer, Bernard H. Bochner, Eliezer M. Van Allen, David B. Solit, and Jonathan E. Rosenberg's Letter to the Editor re: Russell E.N. Becker, Alexa R. Meyer, Aaron Brant, et al. Clinical Restaging and Tumor Sequencing are Inaccurate Indicato
    Eur Urol. 2020 Nov 17. pii: S0302-2838(20)30864.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016